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Cardiovascular disease (CVD) has been a significant health problem worldwide and is the 
leading cause of death globally.  Heart failure (HF) is a chronic progressive form of CVD that 
affects millions of adults in the United States.  The treatment for heart failure is very complex 
and requires an ongoing regimen of medications.  In heart failure, many patients report 
nonadherence to their medication regimens, which leads to a magnitude of preventable deaths 
annually.  With frequent medication nonadherence of the HF patients, there must be an 
intervention used to combat this problem.  The use of telephone-based interventions (TBI) can 
modify nonadherent medication-taking behaviors in the heart failure populations.  This DNP 
quality improvement project utilized a quasi-experimental research design to implement 
Telephone-based Medication Adherence conferences (TBC) at an outpatient HF specialty clinic 
(HFSC) in Little Rock, Arkansas.  The TBC intervention was implemented in HF patients that 
were identified as being nonadherent with prescribed medication regimens through the use of 
Morisky Medication Adherence Sale 8-item survey (MMAS-8) at 1, 2, and 6-weeks following  
routine HF clinic visits.  The goal of implementing TBC was to improve the number of 
medication adherent HF patients at a HFSC in Little Rock, Arkansas by 20% from baseline by 
March 2021. TBC reflected a statistically significant (p= .000) increase on repeated measures 
analysis of variance (RMANOVA) in MMAS-8 scores by more than 52% by week 6 in TBC, 
with an overall improvement across all week scores by 45.3%. The increased MMAS-8 scores 
supports the aims for this DNP project and concludes that TBC does aid in improving medication 
adherence; thus contributing to improved patient outcomes, decreased likelihood for HF hospital 
admissions, reduced healthcare cost burden, and improved mortality in the HF population.   
Keywords: telephone-based intervention, medication adherence, heart failure, telephone-





Implementation of Telephone-based Medication Adherence Conferences to Improve Health 
Outcomes of Heart Failure Patients 
The purpose of this Doctorate of Nursing Practice (DNP) quality improvement (QI) 
project was to improve health outcomes for heart failure (HF) patients at a heart failure specialty 
clinic (HFSC) through the use of telephone-based medication adherence conferences (TBC).  
Medication nonadherence leads to approximately 125,000 avoidable deaths annually (American 
Heart Association [AHA], 2014).  The HF patient population at a HFSC, like the general heart 
failure population, was identified as having frequent exacerbations of symptoms due to 
medication nonadherence.  This DNP QI project sought to explain the incidence and significance 
of nonadherent medication behaviors, a review of the literature used to develop TBC, project 
interventions, methodology, and outcomes following the implementation of the TBC 
intervention.   
Background and Significance 
 
Cardiovascular disease (CVD) has been a significant health problem worldwide causing 
almost 18 million deaths in 2016 and is projected to reach 23.6 million deaths by the year 2030, 
making it the leading cause of death in the world (World Health Organization [WHO], 2017; 
WHO, n.d.).  More than 30 million Americans have a diagnosis of CVD, accounting for more 
than 12% of the United States (U.S.) population (Centers for Disease Control and Prevention 
[CDC], 2017).   
CVD is an umbrella term that accounts for many conditions that affect the heart or 
vascular system including heart failure (WHO, 2017).  Heart failure is a chronic progressive 
CVD, which occurs as a result of the hearts inability to pump adequate amounts of blood to vital 





in the United States (U.S.), heart failure account for 6.5 million adult CVD diagnoses (CDC, 
2019; Savarese & Lund, 2017).  Additionally, one in every eight deaths within the United States 
in 2017 was attributed to heart failure (CDC, 2019).  In the 2015-2017 timeframe, the state of 
Arkansas had 218.7 heart failure deaths per 100,000 overall deaths, which climbed to 220.2 heart 
failure deaths per 100,000 by 2016-2018 (CDC, 2020).    
Due to the high prevalence of heart failure diagnoses, the global economic burden for 
heart failure is around $108 billion dollars per year (Lesyuk et al., 2018).  Of the global heart 
failure expenditures, $65 billion accounts for direct patient care costs and $43 billion is allocated 
for indirect costs (Lesyuk et al., 2018).  The U.S. alone accounted for more than 28% of the 
global heart failure expenditures (Lesyuk et al., 2018).  Direct health care costs in heart failure 
can be described as actual healthcare costs related to medications, hospitalizations, clinic visits, 
and testing (AHA, 2017a).  Indirect healthcare costs include factors like productivity loss from 
an inability to work due to illness, housekeeping costs, and costs of premature mortality (AHA, 
2017a).  The U.S. allocates about $30 billion heart failure expenditures, $18 billion dollars in 
direct costs and $11 billion in indirect costs (AHA, 2017a).  The U.S. expenditure is projected to 
reach over $60 billion, $45 billion for direct costs and $19 billion in indirect costs, by the year 
2035 (AHA, 2017a; CDC, 2019).   
Fifty percent of patients with chronic disease diagnoses are nonadherent with medication 
therapies; with heart failure 29% of patients have reported being nonadherent to their medication 
regimen (Turrise, 2016).  More than 25% of heart failure readmissions within 30 days of their 
previous discharge are related to medication nonadherence (Turrise, 2016).  In addition to a high 
rate of readmission, adherence with designated heart failure regimens is extremely important to 





Heart Association (2014), reports that medication nonadherence contributed to more than 
125,000 preventable deaths each year.  Nonadherence with drug regimens lead to increased 
hospitalizations, clinic visits, anxiety, levels of depression, and risk of mortality (Knecht & 
Neafsey, 2018; Turrise, 2016).   
Therefore, an intervention to improve medication adherence and medication taking 
behaviors among the heart failure population is needed.  Without the implementation of an 
intervention to improve medication adherence, it is likely that patients will experience higher 
healthcare costs, an increased risk of adverse drug reactions, and less than desired health 
outcomes (Knecht & Neafsey, 2018).  The implementation of telephone-based interventions has 
reported to result in a 34% reduction in overall mortality rate of the heart failure patients that 
participate (Inglis et al., 2011).  In addition to a reduction in mortality, telephone-based 
interventions (TBI) can also increase access to specialist care, increase the geographical span of 
patients that are reached, reduce cost of care, and improve patient outcomes (Inglis et al., 2011; 
Knecht & Neafsey, 2018). 
Problem Statement 
The problem statement for this DNP quality improvement project is that adult patients 
who are diagnosed with HF are not adhering to their personalized medication therapy plan 
developed by their heart failure specialist at a HFSC.  As noted in the literature, the HFSC also 
has a problem with patient’s adherence with medication, which must be assessed for the degree 
of nonadherence and an intervention for improvement needs to be developed (Turrise, 2016).  
The HFSC team influencers frequently described the greatest need for improvement 





therapies. Key influencers correlated increased patient medication adherence with lower 
readmission rates due to heart failure type exacerbations.   
Purpose Statement 
The purpose statement for this DNP quality improvement project is to reduce adverse 
medication related events that contribute to complications and hospital readmissions by 
implementing TBC for the heart failure patients at a HFSC in Little Rock.  The telephone-based 
medication adherence conferences were conducted at one week, two weeks, and six weeks 
following an initial clinic visit for heart failure.  The tool sought to identify potential medication 
adherence barriers of heart failure patients and correct any barriers before the patient fails to 
conform to the prescribed medication therapies.  I hypothesized that enhanced adherence to 
prescribed medication therapies will decrease heart failure symptoms and improve quality of life 
for heart failure patients at a HFSC.   
PICOT Question 
In heart failure patients at a HFSC (P), how does implementing routine telephone-based 
medication adherence conferences (I) compared to not using routine telephone conferences (C) 
affect adherence to prescribed medication therapies (O) within ten weeks (T)? 
Needs Assessment 
Objectives 
The objective of the conducted needs assessment was to determine gaps in care for HF 
patients with a HFSC and with primary care providers (PCP) that care for HF patients.  
According to the AHA (2017b), one of the breakdowns in HF patient care is lack of proper 
handoff communication between healthcare providers.  There are more than 5 million HF 





11% of deaths each year in the United States (Ruppar et al., 2017).  This needs assessment 
expected to identify barriers in communication and overall patient care that could improve care 
plan continuity between heart failure providers and PCP’s to improve patient outcomes. 
Participants 
The participants for the needs assessments were chosen based on their amount of 
influence on care provided to HF patients at the HFSC.  Participants included in the assessment 
were key influencers from a variety of disciplines with extensive experience in HF patient care.  
The key influencers encompassed the Medical Director of the HFSC, two registered nurses (RN) 
at the HFSC, a Physicians Assistant (PA) at the HFSC, and two Family Practice APRNs from a 
primary care clinic.  The Medical Director of the HFSC is a Medical Doctor (MD) with a 
specialty in HF and pulmonary hypertension (PH) that was the sole provider of HF for the clinic.  
The two RNs at the HFSC were involved, as they are the direct care team members working 
alongside the Medical Director of the HF clinic.  A PA to the medical director was also 
interviewed as she manages HF patients both in the hospital and outside the hospital.  The two 
PCPs were incorporated, as both are APRNs that work with numerous HF patients in their daily 
practice.   
Rationale of the Needs Assessment 
The rationale for conducting the needs assessment in a HFSC was to discover an area that 
needed improvement in HF patient care and care coordination throughout the HF care 
continuum.  Smeets et al. (2016), described the gap that exists with continuity of care of HF 
patients between interdisciplinary professions.  Many heart failure patients first report to their 
primary care provider for HF symptoms. However, many are often treated inadequately which 





offices (Smeets et al., 2016). In addition, many primary care providers do not have comfort 
providing adequate HF treatments in concurrence with current guidelines (Smeets et al., 2016). 
When patients are seeing a HF specialist, it is important that interdisciplinary care team 
members, such as PCP’s, are all informed of the patient’s care plans to reinforce care from 
different parts of the care continuum due to such specific goals that exist with regard to HF 
treatments (Smeets et al., 2016).  The needs assessment aimed to clarify potential gaps in care 
plans developed in a HF clinic and continued utilization of care plan in the primary care clinic.  
Refer to Appendix B for Initial Process Flow Chart.   
Data Collection Tool 
The needs assessment used key informant interviews to collect information about key 
areas of need for HF patients.  The main factors assessed were the processes being used to relay 
information between agencies, key HF subpopulations that are at risk for poor outcomes, key 
factors that improve quality of care within the HF population, and areas of care plans that need to 
be further elaborated to other providers and patients.  A total of 12 open-ended questions were 
posed to the key influencers regarding current gaps of care with HF patients.  See Appendix K 
for Needs Assessment Script/Questionnaire outlining questions used for interviews with key 
influencers.   
Sample, Sample Size, and Sample Procedures 
 The participants of the needs assessment were selected via a convenience sample with six 
total interviews conducted through open-ended questions about key factors of care for HF 
patients.  The interviews were conducted on February 5th and 11th, 2020 with each interview 
lasting about 20 minutes.   





 All of the interviews were conducted in an office setting with limited distractions in order 
to obtain an unencumbered response.  Participants were given a time to think about their 
responses after questions were conducted, and clarification or examples would be given 
accordingly.   
Data from the interviews indicated that 83% of key influencers felt that patient adherence 
to medication, diet, and follow-ups were the crucial factors of keeping patients from 
readmissions to the hospital.  Similarly, the most frequently reported areas for improvement in 
HF care plans and HF patient involvement, were lack of adherence to diet and medications with 
a mean of 4 and a mode of 4 for both responses.  The participants unanimously reported “no” 
resulting in a mode of 5 describing that there are never calls between the HF specialist and the 
PCP to discuss care plans of HF patients.  The informants were asked if information was being 
given to patients at their follow-up appointments and the modal response was 4 for medication 
changes handouts.  The median answers for the same question of follow up information were all 
tied with 2 responses including diet education, vital sign education, short-term expectations, and 
long-term expectations.    
Conclusions and Action Plan 
 There were common trends noted with the responses from key informants.  A need for 
improvement in care coordination between PCP and heart failure specialists was identified.  The 
greatest need identified from the conducted needs assessment was a need for improvement in 
patient adherence with care plans, specifically with medication regimens.  Based on these results, 
an intervention was developed to improve medication adherence of HF patients at the HFSC and 
will be tested to determine if medication adherence can be improved, thereby improving 





quality of life (QoL) and improvement in long-term health outcomes in HF patients. 
TBC Aim and Objectives 
The aim for this DNP quality improvement project was improve medication adherence in 
heart failure patients through the implementation the TBC intervention.  The goal was to 
improve the number of medication adherent heart failure patients at a HFSC by 20% from 
baseline by March 2021.  Refer to Appendix A for global aim and specific aim statement.  The 
objectives for this project are as follows:  
• To identify all heart failure patients at risk for nonadherent medication behaviors 
at a HFSC. 
• To recognize potential barriers of medication nonadherence. 
• To measure medication adherence at baseline and following implementation of 
TBC through conduction of Morisky Mediation Adherence Scales (MMAS-8). 
• To create a surveillance plan via telephone-based medication adherence 
conferences to aide in improving nonadherent medication behaviors following 
routine heart failure clinic visits. 
• To improve patient outcomes through reduction of hospital admissions by 
improving medication adherence of prescribed heart failure regimens.   
Review of Literature 
 
Search Methods 
MEDLINE Complete and CINAHL Complete, and Google Scholar were used to conduct 
this review of literature. The key population of database searches was patients with heart failure 
diagnoses and the key population was searched in correlation with medication adherence and 





adherence, medication adherence, telephone-based interventions, and health outcomes.  Refer to 
Appendix C for Evidence Table describing strength of articles used.  
Inclusion and Exclusion Criteria 
 Database searches were first evaluated for duplicates from prior searches and duplicates 
were excluded.  All types of studies were permitted in database searches as long as they were 
written in English.  Exclusion criteria included publication years prior to 2015, however, 
exceptions were made with articles published prior to 2015 in circumstances where the article 
was of close relation to the subject matter and discussed thoroughly in an included article.  
Articles were also excluded if they discussed other barriers to care in the absence of medication 
adherence or adherence; or with the main focus on other barriers when medication adherence and 
adherence were discussed.  Exclusions were also made for studies that conducted interventions 
via modes other than telephone or telehealth follow-up.  The results of the database searches 
were all analyzed and inclusion criteria was determined as follows: subject relation to heart 
failure patients, medication adherence or adherence, self-management skills, improved health 
outcomes, discussion of medication adherence or adherence scales, and if they discussed 
telephone interventions for care improvement.  Not all subjects were discussed in every article, 
but articles were evaluated for key topics and included if they were applicable to the study.   
Keywords Used 
 CINAHL Complete was searched with the keywords heart failure and medication 
adherence and medication adherence.  CINAHL Complete yielded 243 articles after exclusion 
criteria were applied.  Of these articles, seven were included in the review of literature based on 
their inclusion of heart failure and medication adherence or adherence.   





and telephone, which resulted in 19 articles after exclusion criteria was set.  Of these articles, 
only five were selected based on discussion of heart failure, medication adherence, and telephone 
interventions.  MEDLINE Complete was then searched with keywords heart failure, medication 
adherence or medication compliance, and Morisky.  This search yielded 14 articles, four of these 
articles were included in the review of literature after duplicates were removed and based on 
their discussion of heart failure in relation to medication adherence or adherence and the Morisky 
Medication Adherence Scale or any other adherence scale.  The keywords used in the next search 
were heart failure, medication adherence or medication compliance, and tool, instrument, scale, 
or measure, which search yielded 80 articles.  Of the 80 articles, nine were pertinent as they 
included information regarding measuring medication adherence or adherence, and eight were 
duplicates from previous searches; so, only one article was included in the review of literature 
from this search.  Lastly, MEDLINE Complete was searched using keywords congestive heart 
failure and telemonitoring, telehealth, or telemedicine.  This search yielded 36 articles, and all 
were reviewed for inclusion of information on heart failure and telephone or telemedicine-type 
interventions.  Of the articles found in this database search, only one article was selected, after 
the duplicates were removed, based on the articles discussion of congestive heart failure and 
telehealth intervention.   
Heart Failure: A Chronic, Progressive Disease 
Heart failure is a clinical syndrome that causes structural and functional changes within 
the heart and associated tissues that result in a decreased ability of the ventricles to properly fill 
or eject blood throughout the body (Knecht & Neafsey, 2016).  As heart failure progresses, it 
causes a complex assortment of symptoms and continues to worsen as patient’s age (Bohm et al., 





ultimately result in a number of symptoms including dyspnea, fatigue, edema, angina, cough, 
nausea, weight gain, and orthopnea (Cui et al., 2019; Granger et al., 2015; Knecht & Neafsey, 
2016; Wu, 2017).  The associated symptoms that occur because of heart failure are ongoing, 
aggravating, and in some cases debilitating to the patient’s normal lifestyle.   
Heart Failure Complexity and Management Difficulty 
Heart Failure management is multifaceted and requires the multidisciplinary presence of 
biomedical care, psychosocial supportive care, individual self-care, and palliative care (Cui et al., 
2019; Uchmanowicz et al., 2019).  The use of a multidisciplinary team can help reduce hospital 
readmission due to complications and can improve outcomes due to the multitude of perspectives 
that can be offered from this approach (Bhimaraj, 2013; Uchmanowicz et al., 2019).   
Medication regimens for heart failure are very complex, as they require at least three to 
four different medications to treat the patient’s symptoms and to decrease overall mortality 
(Bohm et al., 2016; Cui et al., 2019; Knecht & Neafsey, 2016; Krueger et al., 2018; Meraz, 2020; 
Silavanich et al., 2019).  Medication regimens grow in complexity when they are being initiated 
or modified in conjunction with other comorbidities, with patients of increased age and with 
patients worsening severity of diagnosis, all which contribute to medication nonadherence with 
heart failure patients (Bohm et al., 2016; Silavanich et al., 2019; Wu, 2017).   
The term adherence is referred to by the WHO as the extent to which a person’s 
behaviors correspond to the regimens that are prescribed by their healthcare provider (Lam & 
Fresco, 2015; Uchmanowicz et al., 2019).  Medication adherence is a complex and prevalent 
problem in heart failure patients. Medication nonadherence is not always a complete omission of 
a medication, but rather taking lower or higher dosages, temporary discontinuation, permanent 





provider’s prescribed medication regimen (Uchmanowicz et al., 2019).   
Medication nonadherence has a negative effect on symptoms and disease progression; 
and also has been reported as having a negative effect on quality of life in heart failure patients 
(Bohm et al., 2016; Knecht & Neafsey, 2016; Silavanich et al., 2019).  A lack of adherence to 
medication regimens induce worsening of heart failure, further disease progression, and is one of 
the most prevalent reasons for hospital admission due to an acute exacerbation of symptoms 
(Bohm et al., 2016; Dovancescu et al., 2017; Knecht & Neafsey, 2016; Kripalani et al., 2015; 
Wu, 2017). Heart failure medication omission for just 48 hours leads to, “net fluid retention, 
vasoconstriction, a rise in arterial and ventricular filling pressures”, which leads to the visible 
rise of natriuretic peptides in the blood (Dovancescu et al., 2017, p.  647).  The lungs are 
susceptible to fluid retention because of the vulnerability of vascular beds, resulting in shortness 
of breath (Dovancescu et al., 2017).  Heart failure patients note worsening symptoms and 
decreased ability to conduct usual activities without difficulty when these changes take place in 
the body.  According to Knecht and Neafsey (2016), studies have shown that patients were more 
likely to be free of health events when they were adherent with 88% or greater of their 
prescription regimens.   
Factors Related to Medication Nonadherence 
Many patients who do not experience a reduction or cessation of symptoms with 
medications will lose confidence in regimens and discontinue medication use (Granger et al., 
2015). Patients may be nonadherent with medications due to accidental or unintentional reasons.  
For example, the patient may accidentally take medications that they were previously prescribed.  
Although, most heart failure patients are intentional in their nonadherence (Meraz, 2020).  Cost 





instability, lack of transportation, and lack of social support system were the reported 
socioeconomic issues related to nonadherence of medications (Bohm et al., 2016; Cui et al., 
2019; Knecht & Neafsey, 2016; Kripalani et al., 2015; Rehman et al., 2019; Santra, 2015; 
Silavanich et al., 2019; Uchmanowicz et al., 2019; Waters & Giblin, 2019; Wu, 2017; Yeung et 
al., 2017).  Additionally, psychological and behavioral reasons result in nonadherence with 
medication regimens.  Carelessness, forgetfulness, under-education, poor literacy level, poor 
numeracy, lack of belief in medication necessity, feeling no control over medications, and 
cognitive impairments are frequently cited psychological or behavioral reasons for medication 
nonadherence (Bohm et al., 2016; Cui et al., 2019; Kripalani et al., 2015; Meraz, 2020; Paterick 
et al., 2017; Rehman et al., 2019; Santra, 2015; Uchmanowicz et al., 2019; Waters & Giblin, 
2019).   
Many nonadherence factors are related to diseases process, diagnosis, and management.  
Factors related to diagnosis or associated comorbidities include the number of comorbidities in 
conjunction with a HF diagnosis, higher New York Heart Association (NYHA) class, and 
number of years since diagnoses.  Factors related to disease progression and disease management 
include recent hospitalization for exacerbation of symptoms, insufficient care from healthcare 
providers, complexity of drug regimens, experiencing adverse reactions to medications, return of 
symptoms despite medications adherence, and lack of improvement in symptoms with drug 
adherence (Bohm et al., 2016; Cui et al., 2019; Granger et al., 2015; Kripalani et al., 2015; 
Knecht & Neafsey, 2016; Meraz, 2020; Santra, 2015; Silavanich et al., 2019; Turrise, 2016; 
Uchmanowicz et al., 2019; Waters & Giblin, 2019; Wu, 2017).   
Tools for Assessing Nonadherence and Associated Use 





blood concentration levels of HF drugs, patient questionnaires, patient interviews, pill counts, 
electronic monitoring devices, and patient-kept logs (Dovancescu et al., 2017; Krueger et al., 
2018; Lam & Fresco, 2015).  The uses of both subjective and objective measures are useful in 
their individual abilities to measure adherence.  While pairing subjective and objective tools have 
been shown to have the strongest relation to adherence in the patient’s everyday life (Lam & 
Fresco, 2015).  Choosing the appropriate tool for measuring adherence includes factors of 
affordability, ease of use, high reliability, adaptable, and applicable (Lam & Fresco, 2015). 
Objective measures or direct measures have been used to measure the amount of a drug 
within bodily fluids such as blood and urine (Dovancescu et al., 2017; Lam & Fresco, 2015).  
Objective measures are known to be the more accurate type of measures, as they take the bias 
portion of the patient’s report out of the scenario (Lam & Fresco, 2015).  However, in many 
cases objective measures such as blood concentration levels of a drug can be costly and time 
consuming (Dovancescu et al., 2017; Lam & Fresco, 2015).  In addition, this measure can be 
very intrusive to the patient and create a sense of anxiety or distrust (Lam & Fresco, 2015).   
Subjective measures are useful in accommodating a variety of literacy levels, though 
subjective measures in general, are reportedly less reliable than objective measures (Lam & 
Fresco, 2015; Santra, 2015).  Subjective measures include tools like surveys and questionnaires, 
where the patient is giving their own personal account of different subjects of the matter being 
discussed.  Surveys and questionnaires provide researchers with a reasonable and predictive 
capability that is easily completed in fast pace clinics and accounts for limited time during the 
clinical encounter and funding for resources (Dovancescu et al., 2017; Lam & Fresco, 2015).  
Surveys are best administered by in-person interviews between healthcare professionals and 





Fresco, 2015).  Using more than one type of subjective survey to measure adherence does not 
necessarily yield a more accurate result (Lam & Fresco, 2015).   
Morisky Medication Adherence Scale-8 
A frequently used subjective tool to measure medication nonadherence is The Morisky 
Medication Adherence Scale-8 (MMAS-8).  The MMAS-8 is the most commonly used 
questionnaire worldwide. It measures medication-taking behaviors, under use of medication, 
forgetfulness of medication taking, and prompts the surveyor to question the patient about 
potential barriers to medication taking (Lam & Fresco, 2015; Uchmanowicz et al., 2019).  The 
MMAS-8 is often considered when measuring medication adherence with limited funding 
because it is noninvasive, poses minimal burden on the patient, offered in multiple languages, is 
easy to administer, and offers flexibility with time and mode of administration (Silavanich et al., 
2019).  The MMAS-8 is reported as being valid and reliable as it has a Cronbach’s alpha 
reliability score of 0.83, and in terms of the validity of the study, the MMAS-8 has a sensitivity 
score of 93% and specificity score of 53% (Lam & Fresco, 2015; Silavanich et al., 2019; 
Uchmanowicz et al., 2019).  The MMAS-8 Cronbach alpha reliability was higher than many 
other comparable surveys and is one of the top reasons why this survey was chosen (Kripalani et 
al., 2015; Lam & Fresco, 2015). 
Many heart failure patients report having been nonadherent to their medication regimen. 
The MMAS-8 survey was used in a heart failure study by Rehman et al. (2019) and helped to 
identify 23.5% of the studies participants as nonadherent to medication regimens. In one study, 
the MMAS-8 was used to measure adherence to medications and the effect it has on quality of 
life and was able to identify more than 60% of patients as nonadherent to their drug regimens 





to 70% of their study participants with various cardiovascular diseases as having some level of 
nonadherence to lipid-lowing medications.  There are other studies that have used the MMAS-8 
tool to identify large numbers of patients that are nonadherent to their medication regimen 
(Katzmann et al., 2018; Rehman et al., 2019; Silavanich et al., 2019). 
Telephone-based Intervention to Improve Adherence 
A reduced rate of 30-day readmissions among heart failure patients has been linked to a 
post-discharge follow-up visit within seven days (Water & Giblin, 2019).  With such a high 
prevalence of patients with heart failure and heart failure associated hospital admissions, clinics 
have difficulty accounting for all patients that need to receive a clinic visit within seven days of 
hospital discharge.  The use of telephone-based post-discharge appointments can reach patients 
within the critical seven-day period after they leave the hospital.  The use of TBIs resulted in 
fewer rehospitalizations of patients short-term and over a long-term one to three-year span 
(Bhimaraj, 2013).  A meta-analysis of telephone-based interventions with more than over 8,000 
patients in 16 studies noted that TBIs improve medication adherence by decreasing negative 
outcomes, increasing the amount of patients being reached with medical interventions, 
promoting patients to be a team member of their own health management, reducing mortality and 
hospitalizations, and resulting in an overall improved quality of life (Inglis et al., 2011).   TBIs 
that are used to improve medication adherence over a 16-month span result in sustained impact 
on patients for up to three years after the intervention is complete (Bhimaraj, 2013).   
Topics for Beneficial Telephone-Based Interventions 
The use of TBIs such as medication adherence conferences has proven effective in 
inhibiting medication nonadherence (Bhimaraj, 2013).  TBIs should be conducted with 





intervals (Bhimaraj, 2013).  Predetermined components of medication adherence conferences 
should include assessment of dyspnea, fatigue, daily weight results and adherence, edema 
progression, abdominal distention, drug therapy adherence, and level of physical activity 
(Bhimaraj, 2013; Water & Giblin, 2019).  Identification of abnormalities in these predetermined 
components during follow-up correspondence create opportunities for early modifications to 
made to medication dosages to correct these abnormalities before medication nonadherence 
occurs (Bhimaraj, 2013; Water & Giblin, 2019).  Additionally, patients having significant 
problems such as respiratory distress can be identified and prompted to come back to the clinic 
sooner than their scheduled appointment (Bhimaraj, 2013).  Returning to a clinic setting for early 
intervention instead of waiting and going to the emergency medicine setting leads to reduced 
symptoms prevalence, shorter treatment times, shorter if any hospital stays, and improved overall 
quality of life (Wu, 2017). 
In addition to disease processes, all interventions implemented to improve medication 
adherence should be tailored to the patient’s health literacy level (Paterick et al., 2017). To have 
the highest benefit, the patient should be able to understand what they are being taught about 
their healthcare. Health-literacy in combination with tailored patient-provider interactions should 
be used to cater to the patient’s preferences including physical setting of the visits, time available 
for the visit, communication style, content being discussed, mode of information, and concepts 
of healthcare decision processes (Paterick et al., 2017).   
Telephone-Based Medication Adherence Conference Content 
The content of telephone interventions are more successful when geared toward 
simplifying drug regimens, providing patient reminders, improving communication with 





skills, and patient counseling of medications (Cui et al., 2019; Granger et al., 2015; Kripalani et 
al., 2015; Santra, 2015; Waters & Giblin, 2019; Yeung et al., 2017).  Healthcare providers can 
use tools such as education handouts and educational interventions that include medication 
indications, administration practices, disease progression counseling, and common medication to 
aid in improving medication adherence (Yeung et al., 2017).  The implementation phase of TBC 
incorporated the Health Belief Model to educate patients on their disease and the management of 
their disease and tailor questions that prompt patients to modify their medication behaviors and 
beliefs about their medications. The patients was assessed for appropriate medication taking 
skills, medication nonadherence occurrences, reasons for nonadherence, potential tools needed, 
and adverse feelings and symptoms of their medication regimen (Granger et al., 2015; Kripalani 
et al., 2015; Santra, 2015; Waters & Giblin, 2019). By assessing the medication nonadherence 
factors and using the HBM to assess patient medication and disease process beliefs, the patient 
views can be redefined from views of medication burden to shared responsibility and partnership 
in health outcomes (Granger et al., 2015).  
Telephone Interventions Implication for Improved Patient Outcomes 
Innovations should be aimed toward improving medication adherence by providing 
counseling and interventions that improve medication-taking behaviors (Rehman et al., 2019).  
Telephone-based interventions improve medication adherence leading to the reduction of 
mortality rate, morbidity, and hospital readmission (Inglis et al., 2011; Ruppar et al., 2016; 
Rehman et al., 2019).  Overall mortality risk was evaluated by a meta-analysis of 57 HF 
medication adherence studies and found to have a reduction of 10.6% mortality risk when the HF 
patient received some sort of medication adherence intervention (Ruppar et al., 2016). 





patients has shown a 14% mortality risk reduction as reported by Ruppar et al. (2016) and Inglis 
et al. (2011) reported an even higher reduction of 34% reduction in overall mortality rate of heart 
failure patients from TBI.  In addition to a reduction of  mortality, TBIs can also increase access 
to specialist care, increase the geographical span of patients that are reached, and potentially 
reduce cost of care (Inglis et al., 2011). 
Identified Gaps in Care 
There is not a gold standard for how to appropriately measure adherence for patients with 
heart failure as some forms of bias or negative cost-benefit ratio exists (Lam & Fresco, 2015; 
Krueger et al., 2018; Santra, 2015; Turrise, 2016).  In addition, many different adherence scales 
and surveys had varying ideas of what defines medication nonadherence (Granger et al., 2015; 
Kripalani et al., 2015; Krueger et al., 2018; Rehman et al., 2019; Silavanich et al., 2019). The 
majority of researchers agree that medication adherence must be assessed, that the use of claim-
data surveys are the most simple and widespread tool and that while there is not an agreed upon 
nonadherence cut off level, those who have some degree of nonadherence in their survey should 
be further investigated (Krueger et al., 2018; Turrise, 2016). 
Implementation of telephone adherence interventions can pose costs to the healthcare 
agency conducting them.  There has been previous speculation about reimbursement guidelines 
discussing that health insurances may not cover the amount of resources used to conduct 
telephone-based conferences (Lori et al., 2020).  However, Medicaid and Medicare have started 
revising their guidelines to include telehealth in their reimbursement guidelines in the last several 
years to reimburse providers at comparable rates to in person visits (Mehta et al., 2020).  Prior to 
the COVID-19 pandemic, the CMS would provide reimbursement for brief routine care “virtual 





Services [CMS], 2020b). Since the pandemic began, the CMS (2020b) reports that it can now 
provide full reimbursement for telehealth services. With the expansion of telehealth 
reimbursement, TBC can prove beneficial for clinic reimbursement for services.  
Medication regimens and dosing vary, which can create slight bias of data because those 
with higher regimens will likely have increased frequency of symptoms (Krueger et al., 2018). In 
some HF patients, a higher dose of the HF medication regimen may be needed to achieve the 
same affects and improvements as other patient’s experience (Krueger et al., 2018). When the 
dosages of medications are increased, they can be associated with an increase in incident of 
adverse medication reactions. These adverse reaction phenomena could create bias due to the 
adverse effects one patient may exhibit simply due to their higher dose requirement, which could 
lead to an increased risk of nonadherence.   
Lastly, there are inconsistencies within the telephone intervention implementation 
processes. There is not a consensus on the length of time to continue telephone interventions or 
on the intervals at which to conduct telephone follow-ups (Cui et al., 2019; Inglis et al., 2011).    
Some research articles suggest the greatest benefit is to provide patients education and 
medication interventions within the first few weeks of diagnosis (Inglis et al., 2011).  Authors 
Knecht and Neafsey (2016) report that proceeding with medication reconciliation within one 
week of discharge provides an understanding of medication adherence concerns before the 
patient experiences adverse effects from medication changes. 
Theoretical Framework 
 
 Heart failure is an extremely prevalent diagnosis within the U.S. and it requires lifelong 
monitoring and complex medication regimens.  Because 30% of all heart failure patients are 





adherence and further improve quality of life and outcomes (Turrise, 2016).  Many of the 
barriers that exist in medication adherence of heart failure patients are modifiable with the help 
of enhanced approaches by healthcare providers.  A common discussion in the literature 
regarding medication nonadherence in heart failure patients suggest that improving current 
follow-up strategies further increases provider-patient interactions and the frequency of patient 
education and self-management skill promotion opportunities (Yu et al., 2015).  Interventions 
such as TBC aid in improving patient medication adherence behaviors and increase access to 
care, thus decreasing chronic disease related burdens and improve patient outcomes (Inglis et al., 
2011; Yu et al., 2015).  The Health Belief Model (HBM) is a theoretical framework that was 
applied and referenced as a guiding tool for the implementation of TBC to improve medication 
nonadherence in heart failure patients.   
Health Belief Model 
Theoretical frameworks can help shape processes, offer techniques, and model pertinent 
programs for practice implementation for new innovations that are developed to correct health-
related behaviors associated with medication nonadherence (National Cancer Institute [NCI], 
2005).  Theoretical frameworks can tailor quality improvement interventions to account for each 
patient’s individual needs.  More specifically, health promotion theories can be extremely 
beneficial when developing new innovations aimed at improving patient behaviors in those with 
chronic diagnoses (NCI, 2005).  The HBM is a widely used health promotion theory that was 
developed by the U.S. Public Health Service in the 1950’s with the goal of improving patient’s 
health perceptions benefits of avoiding health threats, and influences on individual decisions to 
act on behalf of one’s own healthcare (NCI, 2005). The Health Belief Model has been frequently 





Several theoretical frameworks related to self-efficacy were considered; however, self-
efficacy is only a small portion of the innovation and will not be measured in this project so self-
efficacy models were not chosen.  The Health Belief Model was chosen for this DNP project 
because it provided a theoretical underpinning that was associated with modifying patient 
healthcare behaviors.  A huge portion of improving medication adherence in heart failure 
patients involves an intervention aimed at changing patient behaviors.  Since much of medication 
adherence is related to modifiable and controllable factors decided by the patient, the HBM was 
an appropriate fit because it utilizes a stepwise guide with the aim of influencing patient 
decisions through their own thoughts and beliefs (NCI, 2005).  See Appendix D for the 
Theoretical Framework model and Appendix E for this project’s Conceptual Model.   
Carrying Out the Health Belief Model 
 The HBM is a six-construct model that has been created based on noteworthy patient 
decision influences (NCI, 2005).  The theory explains that those who are ready to improve their 
actions will exhibit characteristics from all six domains (NCI, 2005).  The six constructs include 
perceived susceptibility, perceived severity, perceived benefit, perceived barriers, cue to action, 
and self-efficacy (NCI, 2005). During the implementation phase of TBC, there were many 
questions that were used to assess the patients continued medication adherence. All the 
questions used during TBC were reflective of the constructs of the HBM, refer to Appendix I to 
view TBC Script detailing questions asked during follow-up calls.  
Construct 1: Susceptibility 
 Perceived susceptibility is the extent to which the patient believes they are susceptible to 
the condition (NCI, 2005).  In heart failure patients this can be noted by determining what the 





susceptibility was noted in a medication adherence survey.  The medication adherence surveys 
were used to determine those with nonadherent behaviors needing intervention with TBC.  
During the implementation phase of TBC, the patient was assessed for susceptibility via 
questions such as medication importance and concerns they had about their diagnosis or 
medications.  
Construct 2: Perceived Severity 
 The second construct in the HBM is the patient’s perception of the severity of their 
condition and the associated consequences (NCI, 2005).  In the heart failure population 
perceived severity is recognized as the patient’s opinion regarding the severity of the 
consequences when they do not take their medications, such as the symptoms they experience.  It 
was noteworthy in the medication adherence questionnaire portion of the TBC innovation, but it 
was also used in telephone conferences to explain to the patient the importance of taking their 
medications, as they did not want to have associated side effects.  During the implementation 
phase of TBC perceived severity was assessed via questions related to what adverse effects they 
were having and what had happened positively or negatively as a result of their medications.  
Construct 3: Perceived Benefits 
 Perceived benefits can be described as the patient’s belief that taking care of their own 
health can reduce their susceptibility to the condition or the severity of their condition (NCI, 
2005).  Perceived benefits can be noted in heart failure patients as the observed elements that 
would help the patient improve their medication adherence.  Perceived benefits were represented 
in this project with the implementation of TBC.  Telephone-based Medication Adherence 
Conferences were used with the aim of aiding patients in taking their medication more 





thereby improving overall health.  Perceived benefits were noted in the TBC implementation 
phase through questions that asked patients to explain how they remember to take their 
medications and if they felt they were benefiting from their medications.  
Construct 4: Perceived Barriers 
 The perceived barriers within the HBM can be described as the patient’s perception of the 
cost outweighing the benefits of acting on their health care (NCI, 2005).  Perceived barriers for 
this project were patient perception of barriers to adhering to medication recommendations, such 
as cost, side effects, and complexity.  Perceived barriers were discussed in the review of 
literature, the medication adherence surveys, and during the implementation of TBC.  The 
patient’s perceived barriers were assessed during TBC implementation when assessing the 
reasons they had for not taking their medications.  
Construct 5: Cue to Action 
 Cue to action is the exposure to disease factors that prompt patients to take action on 
factors of diagnosis (NCI, 2005).  The cue to action step within HBM can be noted within TBC 
as the types of interventions currently in place to prompt the heart failure patients to take their 
medications.  The cue to action step in this DNP project was aligned with the implementation of 
TBC, which served as a reminder to the patients that taking medications is important and 
provided an opportunity for healthcare providers to help the patient brainstorm ways to 
remember to take medications.   The cue to action HBM step can be additionally noted in the 
implementation of TBC through questions regarding ways they felt they could be helped with 
medication adherence behaviors.  
Construct 6: Self-Efficacy 





in their ability to successfully perform healthcare actions (NCI, 2005).  Self-efficacy in this DNP 
project was a measure of how capable the patient felt in adhering to prescribed medication 
regimen.  Self-efficacy was identified in medication adherence surveys as well as reinforced 
during TBC.  Self-efficacy was assessed during the implementation phase of TBC by asking the 
patient questions regarding their comfort with their medication regimens.  
Health Belief Model Effects on Telephone-based Medication Adherence Conferences 
 The HBM is a guide that can be used in patients with a variety of diagnoses.  HBM 
provides a thorough narrative of the patient’s perceived benefit of their diagnosis, and guiding 
steps on how to tailor treatment plans to the patient’s beliefs (NCI, 2005; Yang et al., 2016).  
Perception and behaviors are extreme driving forces of medication adherence in heart failure 
patients and can be further elaborated with the use of the Health Belief Model (Yang et al., 
2016).  A commonly reported reason for medication nonadherence is flawed psychosocial 
stability and support, which elaborates the need for the inclusion of the HBM when developing 
an intervention for medication adherence improvement (Knecht & Neafsey, 2017; Kripalani et 
al., 2015; Meraz, 2020; Yeung et al., 2017). Poor medication adherence leads to increased 
symptoms and increased hospitalizations, which have been linked to poor quality of life (Santra, 
2015; Silavanich et al., 2019). In a study of patients with hypertension and medication 
nonadherence, Yang et al. (2016) reported that the HBM was beneficial in identifying the 
psychosocial factors that drive medication nonadherence and helped to improve those factors. 
When implementing TBC, medication adherence was more likely to be successful with the use 
of HBM as it was heavily weighted on patient’s perceptions.  Patients beliefs are driving forces 
for medication adherence; telephone-based interventions have been noted to improve patient 





in the heart failure patient population (Bennett et al., 1997; Harter et al., 2016; Kripalani et al., 
2015; Santra, 2015; Silavanich et al., 2019).  With the identification of flawed HF beliefs 
through the HBM and the associated medication nonadherence as described by Yang et al. 
(2016), an educative innovation such as TBC that aims to improve medication and disease 
process beliefs through patient education had the opportunity to help improve medication 
adherence and thus improve patient outcomes.  
Methodology 
Project Description  
 This DNP QI project utilized a quasi-experimental research design to improve patient 
outcomes through the implementation of telephone-based medication adherence conferences by 
increasing medication adherence practices in heart failure patients at an outpatient HFSC.  The 
quasi-experimental approach was a suitable experiment design type in this clinical practice 
settings due to the utilization of an independent or treatment variable only, did not require 
randomization, and did not require an experimental group or control group (Melnyk & Fineout-
Overholt, 2019; Moran et al., 2017). A non-randomized quasi-experimental sample method was 
selected for this project since the participants were identified based on their level of 
nonadherence through a medication adherence survey, and were not being broken down into a 
treatment and control group, which made the approach a more appropriate option due to the 
initial narrowing characteristic of the project design (Melnyk & Fineout-Overholt, 2019).   
 The DNP project consisted of a pre- and post-intervention administration of the MMAS-8 
survey to heart failure patients at the HFSC.  The pre-intervention MMAS-8 established the 
patient’s level of medication adherence deeming them either adherent or nonadherent.  The pre-





were equal at baseline, meaning they were all nonadherent regardless of the degree of 
nonadherence (Melnyk & Fineout-Overholt, 2019).  All patients noted as nonadherent were 
classified the same regardless of the level of nonadherence on the MMAS-8, meaning they were 
all listed as non-adherent and were given the same intervention despite their scores.  The post-
intervention MMAS-8 survey was administered to determine the success of the intervention in 
reducing nonadherence in the patients who receive the TBC intervention at 1 week, 2 weeks, and 
six weeks after the intervention began (Melnyk & Fineout-Overholt, 2019).   
 The desired result of the quality improvement project was to improve patient outcomes 
by creating and implementing TBC to increase medication adherence in heart failure patients at a 
HFSC by 20% from the baseline by March 2021.  The DNP project attempted to characterize the 
impact of implementation of TBC on patient outcomes, disease progression, and hospitalizations; 
and did so in concordance with the goals and objectives of care provided by the heart failure 
team.  In order to achieve project objectives, TBC was implemented after the completion of a 
pre-intervention survey phase and was then compared to the post-intervention survey phase to 
evaluate effectiveness.  The project had the potential to reach over 400 HF patients at the HFSC 
with TBC during the implementation span, however I was prepared for not all patients to be 
willing to consent, and not all patients seen in the clinic possessed a nonadherence score on the 
MMAS-8 survey.   
Project Design   
 The DNP project was a QI project designed to improve health outcomes in the HF 
patients through the detection of medication nonadherence, implementation of treatment 
guidelines with TBC, and measurement of improvement for the specific health service provision 





project did not deduce original information regarding medication adherence in heart failure; 
rather it monitored the implementation of TBC an evidence-based innovation, to improve 
medication adherence and health outcomes in HF patients (Hickey & Brosnan, 2017).   The 
specific outcomes that were assessed to evaluate the effectiveness of TBC included changes in 
improvement in medication adherence as detailed by improved post-intervention MMAS-8 
survey results, as well as the lack of hospitalizations in project participants detailed by patient 
reports.     
Setting  
 The setting of the DNP QI project was in Little Rock, AR at one of the largest 
cardiovascular specialty outpatient clinics in Arkansas, that sees thousands of patients every 
year.  The project was implemented via outpatient heart failure visits and through telephone-
based conferences, which were conducted wherever the patient was located.   
Study Population  
 Participants of the study included patients with a new or existing diagnosis of heart 
failure.  See Appendix L and M for Recruitment Script and Patient Consent Form that were used 
for participant selection. The sample size for this project was unknown prior to implementation 
since it was dependent upon the number of clinical visits scheduled per day and the attendance of 
scheduled visits, although the heart failure clinic sees from 20-60 HF patients per week.  The 
sample size of TBC included 12 participants. Convenience sampling was used, as there was not 
an adequate opportunity for randomization; every heart failure patient received the same survey 
to determine if inclusion criteria were met.  Additionally, lack of use of randomization was an 
attempt to gain a larger treatment group.   





 The DNP project intervention was the implementation of TBC in heart failure patients at 
a HFSC in Little Rock, AR.  Patients were screened for medication adherence during routine 
heart failure visits.  During the visit, patients were consented for inclusion in the study and then 
received a MMAS-8 survey to complete independently or with the help of the HFSC staff.  
Patients who had survey results that concluded medication nonadherence then were selected as 
participants of the TBC intervention.  At the initial visit, the patient was educated about the 
study, the specifics of the TBC intervention and its components, and was educated on their 
medications and the importance of complying with regimens. TBC intervention was then 
implemented at 1-week, 2-week, and 6-week intervals following their initial clinic visit in an 
attempt to improve medication adherence.   
 Pre-Implementation Phase.   During the pre-implementation phase key stakeholders 
and HF team members from the projects needs assessment were contacted, and I conducted team 
discussions with the heart failure team, to converse about current clinic processes and discuss 
plans for feasibility of the TBC intervention implementation.  Based on feedback from the heart 
failure team meetings a process map was modified to identify areas of need and improvement 
opportunities for the heart failure patients at the HFSC.  I then met with the heart failure team to 
discuss the use of MMAS-8 and any potential barriers that were noted with the survey’s 
implementation, though none were identified.  I then conducted an educational meeting with 
heart failure specialist to explain the background and significance of medication nonadherence, 
the potential implementation start date, project phases, and the proposed steps of the project 
meetings with staff.  The initial meeting occurred prior to implementation and captured all of the 
heart failure team and was conducted after clinic had commenced.   





specialist and project chair.  After modifications of the TBC intervention were made, a finalized 
topic inclusion plan was completed to guide telephone conferences during the implementation 
phase.  A conclusive meeting was held by me to discuss the finalized TBC topic inclusion plan 
and goal start date.  
When barriers arose during the implementation of TBC, I managed them, and 
modifications were made through Plan-Do-Study-Act (PDSA) cycles. The plan for evaluation 
and identification of success was then established and project measures reflected the potential for 
success. Key stakeholders and the heart failure team members approved the finalized 
implementation plan for TBC prior to implementation.    
 Implementation Phase.  At the beginning of the implementation phase, patients who 
came to the HF clinic for routine follow-ups completed a MMAS-8 survey with the help of the 
PI or nursing staff during triage. I then scored the MMAS-8 survey and identified of patient with 
nonadherent scores and the results were entered into the electronic health records (EHR) stored 
on the clinic computer.  When the patient’s score reflected nonadherent behaviors or beliefs, I 
met with the patient about the TBC QI project. During the TBC QI project discussion meeting I 
explained the goal of the project, TBC plan, and timeline for the project. When the patient was 
willing to be included in the study, the patient completed a consent form in order to participate in 
the TBC intervention. The patient then underwent a brief education session about their heart 
failure diagnosis including what heart failure means, the patient’s heart failure medication, 
medication side effects and reasons for use, medication dosages and frequencies; and reinforced 
the project plan including plan for follow-up telephone conferences at 1 week, 2 weeks, and 6 
weeks following the initial visit. Refer to Appendices I, J, and K for Educational Materials 





Survey.   
It was important that all heart failure patients at the clinic received and completed the 
MMAS-8 survey.  In order to reduce process abnormalities, I ensured that surveys were 
completed with all heart failure patients, the surveys were completed correctly, and the results 
were entered into the EHR conducted weekly assessments.   
Once the patients were identified as being nonadherent with medications through the 
MMAS-8 and consented for participation in the study, I then contacted them via telephone 
conference at 1 week, 2 weeks, and 6 weeks following their initial visit.  Patients was assessed 
for and assisted with complications associated with their medications including side effects, 
dosages, frequency, current medication taking skills, needs for medication modifications.  I 
reviewed disease processes with the patients, recent hospitalizations, vital sign and weight 
measurement consistency, and identification of factors related to medication nonadherence. At 
each telephone conference, I recorded data on key topics discussed, any educational pieces 
completed with the patient such as disease process, medication dosages, medication side effects, 
medication frequencies of administration, complication occurring with patient related to 
medications or new complications of their HF, and identified factors related to medication 
nonadherence. During the final telephone conference with the patients, they completed the 
MMAS-8 survey again with me as a post-intervention measure, which concluded the 
implementation phase.    
 Post- Implementation Phase.  After the implementation phase of TBC was completed, 
all post-intervention MMAS-8 survey data was analyzed.  During this phase, all remaining data 
was entered into data collection sheets and patient identifiers were removed after recording. A 





data. Consultations with the University of Arkansas Statistical and Measurement Support 
Services (SMSS) staff were utilized to review and conduct statistical testing with data that was 
collected in the study. Once data analysis was completed, the results were disseminated with the 
University project team, HF clinic staff, and stakeholders.     
Study Measures 
 Conceptual Definitions.   The conceptual definition of medication nonadherence or 
nonadherence is the action of omitting or changing medication dosages that were prescribed for 
the HF management of the study participants. The conceptual term heart failure is defined as the 
definitive diagnoses of either systolic or diastolic heart failure with an identified NYHA group 
and class.  The conceptual definition of improved health outcomes is the positive effects or lack 
of negative effects that patient’s experience, monetary cost changes, hospital admissions, and 
mortality as a result of complying with prescribed heart failure medication regimens. The 
conceptual definition of telephone-based medication adherence conferences is described as a 
follow-up conference after an initial routine heart failure clinic visit that is conducted via 
telephone and both identifies and addresses factors associated with medication nonadherence.   
 Operational Definitions.  The operational definition of the term medication 
nonadherence or medication nonadherence is the MMAS-8 survey score, which depicts 
nonadherence to medication recommendations. The operational definition for heart failure as it 
pertains to this study describes any patient who is seen at the outpatient clinic for a routine visit 
that is being evaluated for newly diagnosed or previously diagnosed heart failure and is being 
considered for the addition of guideline-directed medical therapy (GDMT). The operational term 
for guideline-directed medical therapy is defined as the use of any or all of the four drug classes 





neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonists, and Sodium-glucose 
Cotransporter-2 (SGLT2i) inhibitors.   
 Outcome Measures.  Outcome measures quantify how well TBC met the specific aim 
with implementation the intervention (Melnyk & Fineout-Overholt, 2019).  The outcome 
measures for this DNP project included the number of heart failure patients who have an 
MMAS-8 survey indicative of nonadherence to medication, medication nonadherence variables 
discussed during patient interviews, demographic data specific to all patients within the study, 
and the percentage of improvement in medication adherence as a result of TBC.  Pre- and post- 
implementation MMAS-8 survey results were a crucial outcome measurement tool for 
determining a change in medication adherence.  Variables of nonadherence identified included 
things such as symptoms associated with taking medications, affordability of drugs, and 
forgetfulness.  Nonadherence variables were assessed via a questionnaire that was administered 
to all patients included in the study.  Refer to Appendix J for Medication Nonadherence 
Questionnaire and Appendix K for MMAS-8 Survey.   
Process Measures.  Process measures investigate each step of the proposed intervention 
to ensure it was implemented as it was intended assisting me to maintain competency and 
productivity.  The project used the Plan-Do-Study-Act technique to plan the project, implement 
the intervention, analyze the interventions effectiveness, and make revisions to the project as 
barriers occurred (Melnyk & Fineout-Overholt, 2019; Moran et al., 2017).    
The process measures for this DNP project included the amount of participation from 
patients in the TBC intervention at each of the scheduled intervals and the consistent adherence 
of registered nurses with administering the surveys.  One process measure for this DNP project 





TBC intervention at 1 week, 2 weeks, and at 6 weeks. This project aimed to have 75 percent 
participation of patients in TBC by week 6 of implementation. The other process measure 
included the nurses’ adherence and myself with survey administration as monitored by me via 
weekly chart reviews in order to ensure that the intervention was implemented as intended.  The 
project aimed to have 95 percent adherence with MMAS-8 survey conduction by the site 
champions.  
Balancing Measures.  The balancing measures of the implementation of TBC were used 
to determine unintended positive and negative effects of project implementation.  The balancing 
measures included the amount of hospital admission rates during TBC implementation, an 
increase in medication nonadherence, the amount of time to complete pre-implementation tasks, 
and the potential influx in patient correspondence with the clinic as compared to pre-
implementation.  The identified balancing measures were important for this study because they 
were potential negative events that can occur, which had the potential to skew the results of the 
study.   
Benefits and Risks   
 The benefits of this DNP project included improved patient outcomes such as reduced 
hospital admissions, reduced disease progression, and reduced morbidity and mortality as a result 
of amended medication nonadherence (Inglis et al., 2011; Rehman et al., 2019).  The 
implementation of TBC incurred minimal risks to the patient or their associated outcomes.   
Potential physical harm risk could have occurred in study participants who were 
previously untruthful about their degree of adherence, as increases to their regimens could have 
been made previously, and they would be taking medications that were too high in dosing.  The 





patients identified as nonadherent whom high dose medication regimens ordered. In said 
patients, reduced dosages and changes could have been required as to avoid potential adverse 
medication reactions. 
The emotional, social, and psychological risks were low for TBC implementation; 
however, there was potential for the patient to experience negative feelings as they had more 
monitoring of their accountability in medication adherence. The patient’s negative feelings were 
addressed by ensuring appropriate word choice that does not insinuate blame or wrongdoing and 
simply aimed to help and aid the patient in success.   
Economical costs of TBC intervention did not have the potential to affect the patient as 
they were visiting the clinic despite TBC and the patient should have already been incurring the 
medication regimen costs, though they could have experienced the costs due to adherence of 
prescribed therapies with TBC intervention.  
Subject Recruitment 
All participants of TBC were patients with HF who had an MMAS-8 survey that reflected 
medication nonadherence.  Prospective data was collected via patient interviews during their 
initial clinic visit and via telephone conferences.  The patients were identified, received an 
explanation of the study and its components, and were consented prior to the implementation of 
TBC. Refer to Appendix L for Recruitment Script.   
Consent Procedures  
 This DNP QI project utilized an informed consent document for any patient who was 
identified as nonadherent with MMAS-8 that agreed to participate in TBC implementation.  See 
Appendix M for Patient Consent Form used.   





 For this DNP QI project there was no costs incurred by the participants above the cost of 
their regularly scheduled clinic visit.  Compensation for project participation was not permitted 
during the project in any phase.   
Project Timeline 
 The DNP project took place after approval by the Institutional Review Board (IRB) 
committees from the University of Arkansas and the HFSC by January 2021 and was completed 
in March 2021.  See Appendix F for details of Proposed Gantt Chart, Actual Gantt Chart and 
Compared Gantt Chart.  
Resources Needed and Economic Considerations  
 The DNP project had minimal associated costs for implementation.  Less than $100 was 
spent to provide educational materials and written consent forms.  See Appendix S for TBC 
Budget. TBC interventions posed minimal costs to the HFSC as they already pay for telephone 
services to run daily clinic needs.  The implementation has the ability to bring in revenue long 
term as many insurance companies are reimbursing for telephone and telemedicine visits (Lori et 
al., 2020).  Additional resources used by myself included a computer at the clinic used to record 
data, Microsoft excel, Microsoft word, and Internet data; addition resources had no additional 
costs for the project’s implementation.    
Implementation 
Study Interventions  
 The implementation process for TBC was planned and was executed by the heart failure 
team members and myself the principal investigator. During implementation the project required 
weekly corrections to enhance the project results. Weekly meetings were carried out between me 





needed to best meet process, outcome, and balancing measures. Refer to Appendix G for 
Statement of Mutual Agreement for DNP Guidance, which reflects those involved in project 
development and evolution. A Plan, Do, Study, Act approach was used throughout the project to 
evaluate and correct project flaws for the remainder of the project. The implementation 
processes, PDSA cycles, timelines, and identified barriers or changes will be discussed in depth. 
Refer to Appendix N for Project Implementation Table, which details the project evolution over 
time.  
Pre-Implementation Phase  
 Before implementation occurred, the project required approval by both the University of 
Arkansas Institutional Review Board (IRB) and the clinic site IRB. The IRB approval process 
took longer than initially planned, which caused shifts in the project timeline. The project 
proposal was submitted to University IRB on October 12, 2020 and approval was received from 
the University IRB on November 17, 2020. Once approval was obtained from the University IRB 
the project proposal was then submitted to the clinic IRB on November 24, 2020 and approval 
was received from the clinic site IRB on January 14, 2021. Based on the changes required from 
the clinic site IRB, an amendment was needed for the proposal package from the University IRB; 
the amendment was submitted for authorization on January 9, 2021. While waiting for final 
approval from the University IRB, I conducted education sessions with the clinic staff, 
developed patient education folders for the initial clinic visits being conducted with patients, set 
up data collection sheets, created storage locations on the clinic site computer, and determined 
the tentative timeline for patient inclusion based on the delayed IRB approval. The University of 
Arkansas IRB issued the final approval for implementation on January 19, 2021 and 





Implementation Phase  
 Throughout the implementation phase, I conducted the main components of patient 
interactions. The HF team was available and coordinated with me regarding which patients were 
being seen for a HF diagnosis, patient location, and timing for the visit so that I was able to 
assess all HF patients for nonadherence.  
Initial MMAS-8 Conduction. When the patient presented for their regularly scheduled 
appointment at the HFSC, the HF team triaged the patient and introduced me. I then explained to 
the patient that the HF specialist and myself were partnering to improve the identification of 
patients who were having difficulties with their medication regimen. I then conducted the initial 
Morisky Medication Adherence Survey (MMAS-8), which consisted of eight questions 
regarding the patient feelings and actions with medication adherence. Refer to Appendix K for 
MMAS-8 survey. The maximum score reflecting complete adherence was an eight out of eight 
points. Patients who scored less than eight on the MMAS-8 were deemed nonadherent in some 
capacity and I advanced to subject recruitment.  
Subject Recruitment. For patients with MMAS-8 scores that reflected nonadherence, I 
utilized the subject recruitment script to discuss the details of the study with the patient. Refer to 
Appendix L for Subject Recruitment Script. The subject recruitment script outlined the purpose, 
processes, and a brief summary of what the project was to include. The patient was then given 
the opportunity to ask questions about the project and I addressed any barriers or apprehensions 
as needed. If the patient was willing to participate in the project, I proceeded to the consent 
process.  
Patient Consent. The patient consent process included the discussion of my roles, patient 





project plan with follow-up phone calls. Refer to Appendix M for the Patient Consent Form. 
Once the patient signed the consent form and acknowledged an understanding of the materials, I 
began the initial education session.  
Initial Data Collection and Patient Education Session. The initial education session 
had multiple components that were completed between the patient and myself. The patient was 
first asked to complete the Medication Nonadherence Questionnaire so that I could determine 
patient specific medication taking barriers that existed for the patient. Refer to Appendix J for the 
Medication Nonadherence Questionnaire. Next, I collected demographic data from the patient 
that was not listed in the electronic medical record (EMR) such as highest level of education, 
marital status, family support person, and employment status. I also assessed the best time of day 
for the patient to be contacted and the best phone number to reach the patient for the TBC 
follow-up calls.  
 After all questionnaires, demographics, and contact information were collected, I started 
with the patient’s education session. The patient received a tailored educational folder that 
included the HF Quick Reference Guide, individual medication education packets, as well as a 
HF overview and disease education packets. Refer to Appendix I for Educational Materials and 
HF Quick Reference Guide. The patient HF Quick Reference guide was discussed the most 
thoroughly as it is a handout that condenses all the medications and HF disease symptoms in one 
place. I wrote each individual HF medication including brand name and generic name that was 
prescribed by the HF specialist with updated dosages, medication purpose, frequency, and any 
special instructions for the patient to remember in the table on the HF Quick Reference guide. I 
explained the symptoms to monitor for based on the HF Quick Reference Guide and when to call 





they had about their medications or project plan and I responded accordingly.  
Initial Education Commencement Conference and Recording. After the education 
session was completed between the patient and myself, the patient was dismissed from the clinic. 
I then conducted commencement conferences with the HF team. The conferences included a 
brief discussion between the HF specialist and myself to discuss the identified nonadherent 
patients and any factors or barriers that existed with their medication regimen. During the 
conference, the HF specialist had the opportunity to give me feedback or notes to address with 
the patient at follow-up phone calls. I then computed all collected data in Microsoft Excel and 
Qualtrics for data analysis. Refer to Appendix H for both Patient Specific Data Collection Sheets 
and Total Patients Data Collection Sheet.  
TBC Follow-up Calls at Week 1, Week 2, and Week 6. After the initial recruitment 
and education sessions were completed, I then called the patient for their Week-1 TBC follow-up 
call. During the follow-up call I used the TBC Script to guide the conversations with the patients 
addressing a number of questions about their current medication regimen and any barriers they 
were experiencing. Refer to Appendix I for the TBC Script used during follow-up phone calls. 
After the TBC script was completed and all patient questions were answered, I administered 
another MMAS-8 survey to assess any change in medication adherence as compared to the first 
visit. When the TBC script and the MMAS-8 were completed, the call was ended, and I 
reminded the patient when the next scheduled contact was going to take place. The process was 
repeated at all proceeding TBC follow-ups at Week-2 and Week-6.   
Reviewing Processes and Measures   
The TBC intervention was monitored extensively through outcome measures, process 





interaction and entered into patient specific data collection sheets as well as through deidentified 
inputs into Qualtrics survey entries. Refer to Appendix H for Patient Specific Data Collection 
Sheets. As the study progressed, I had an advisement meeting with the Statistical and 
Measurement Support Service (SMSS) staff at the University of Arkansas, which took place 
during week four of implementation. During the advisement the SMSS staff recommended the 
need for developing an overall project data collection sheet that included deidentified data for 
every patient in one location versus the previously used sheet that had an individual data 
collection tool for each patient.  The new data collection sheet inclusion comprising all patients 
in one sheet, allowed for simplification during the data analysis process at the conclusion of the 
project. Refer to Appendix H for Total Patient Data Collection Sheet. All data was recorded on 
the patients within twenty-four hours of their interaction with myself and all data for total 
deidentified data collection was completed at least weekly.   
 I discussed the progress with HFSC team including the HF specialist each week in an 
informal meeting to correct barriers or identify any needs that existed in order to improve 
implementation. I also deliberated weekly progress with the project committee chair to discuss 
potential flaws in process, outcome, or balancing measures. There were very few modifications 
needed for project measures; many of the modifications needed were in relation to human 
components rather than project components. The recognized changes were elaborated in Plan-
Do-Study-Act (PDSA) cycles. 
Plan-Do-Study-Act Cycles 
 Despite the planning that was conducted to allow the project to unfold in a smooth 
manner, there were unforeseen matters that required attention throughout the project 





study processes but rather components related to human errors. Regardless of the obstacle, I 
developed an individualized PDSA cycle weekly to address the identified flaws in the study. See 
Appendix O for all PDSA Cycles.  
Declination of Project Participation. One unforeseen factor identified during 
implementation included limited participation of patients in TBC as a few patients declined 
inclusion in the study. I addressed the participation barrier by reflecting on the wording used to 
approach patients when attempting to gain inclusion in the study. In addition, I missed 
demographic questions during initial interviews in the first week of implementation that needed 
to be included moving forward, highlighting the areas on paper so that I would easily recognize 
them amended these questions. For the questions that were missed, I proceeded to ask the 
omitted demographics at TBC follow-up calls.    
Reduced Project Sample Size. A big factor identified by myself was that the study 
yielded a much smaller sample size of patients in TBC than anticipated, which was majorly 
affected by the late IRB approval. Due to the small sample size, I also had to reevaluate the 
planning of data analysis, as not all statistical measures are appropriate with smaller sample 
sizes. I sought out advice from the SMSS staff at the University of Arkansas to develop new 
plans for data analysis during the post-implementation phase of the study.  
Lack of Follow-up Call Participation of Patients. I experienced a barrier related to lack 
of participation in follow-up phone calls. This barrier was anticipated during the planning phase 
and I purposely asked the patient a time of day to call and a good phone number to be reached 
with during the initial clinic visit. Despite these preparations, I still experienced many patients 
that did not answer for follow-up phone calls. To combat this barrier, I continued trying to call 





day after their scheduled date as needed in order to find a better day or time that the patient could 
be reached. When or if the patient was eventually reached, I scheduled a day and time that would 
work best for the proceeding follow-up calls.  
Medication Nonadherence Detection Barrier. I also identified a barrier in the detection 
of all patients who were nonadherent with medication. The MMAS-8 is used to detect reported 
medication adherence to a degree determined by the patients’ views on their own adherence. I 
identified many patients who had had accidental omissions that were discovered by the clinic 
staff or identified during medication reconciliation at the clinic visit. In this group of patients, 
many of them still reported MMAS-8 surveys reflecting complete medication adherence. In 
future studies, the researcher should consider including other tools for detecting the population of 
patients that may be nonadherent despite their MMAS-8 score.  In addition to the MMAS-8, I 
could include a section of questions for the researcher to answer about the patient. An example 
of a question for the researcher to include when assessing nonadherence would be, “Does the 
patient have any non-reported factors of nonadherence?” Some samples of detectable 
nonadherence factors would include clinic to pharmacy correspondence revealed nonadherence, 
patient accidental omission of a prescribed medication, or the patient reported taking a different 
dose than was prescribed. If the researcher answers yes to the included question, they should 
then explain to the patient what the reasoning for deeming the patient nonadherent and attempt to 
include the patient in the study.  
Limited Access of Patient Information. The last identified barrier during 
implementation was my lack of access to TBC patient data outside of the clinic. Prior to the IRB 
approval process, I intended to store data on a password protected and encrypted electronic data 





patients outside of clinic hours. However, the clinic IRB preferred that data not leave the clinic 
while patient identifiers were still in place. In order to gain IRB approval, I determined that all 
TBC follow-up calls would have to be made from the clinic, as patient identifiable information 
was needed to complete the follow-up calls. The lack of access to TBC patient data outside of the 
clinic proved to be a barrier of the project as the clinic was forced to close due to inclement 
weather for one week during project implementation, rendering me unable to complete follow-up 
calls at their regularly scheduled interval.  
Interprofessional team dynamics 
 The interprofessional team within the clinic setting included myself, the heart failure 
team, which was comprised of the HF specialist, two HF nurses, the clinic project manager, and 
clinical informatics specialist. All HF team members were vital to the project success at the 
HFSC. I was also in weekly correspondence with the project committee chair that worked 
diligently to improve project outcomes and troubleshoot project barriers as they were identified.  
Every member of the team performed a crucial role in making the project run smoothly and 
ensured there were limited barriers during the implementation process.  
 Communication between the HF team and myself took place weekly and in some cases 
daily, to ensure barriers were being addressed and interprofessional team member dynamics were 
functioning smoothly. Most communication took place face to face and all patient information 
was communicated in accordance with HIPAA.  
Process Flow Chart Variation  
 The process flow in assessing and correcting medication nonadherence included many 
changes throughout the implementation process. All of the changes required action from TBC 





measures were intertwines in the original process flow the outcome measures improved. See 
Appendix B for the Upgraded TBC Process Flow Chart.  
 The TBC intervention process began in the flow process at the level of the clinic visit for 
follow-up with or without recent admission to the hospital. The patient was then assessed for 
nonadherence with the MMAS-8 survey during care plan development at the clinic visit. If the 
patient was identified as nonadherent they were assessed for willingness to participate, consent 
was completed for participation, and they were educated thoroughly about their patient specific 
heart failure medication regimen, which is reflected in Appendix B Upgraded TBC process flow 
chart.  
 The patient was then sent home and the expectation was that they would follow along 
with the modifications and educational foundations instilled in them at their initial clinic visit, 
which was previously part of the process flow but was expanded upon with the detailed 
education session. A change also occurred in the patient’s possession of the TBC folder resource 
for guidance at home as described in the upgraded TBC process flow chart. The original process 
included the patient becoming nonadherent to medications once returning home and resuming 
normal activities, however this was a major milestone to be modified which included the follow-
up TBC calls from myself to the patient. During the phone calls the TBC intervention was also 
built to include symptom detection so that changes were made with medications to improve 
symptoms before nonadherence or hospitalization became a factor. The education was then 
completed for all changes made during TBC follow-up calls. After the additional education, the 
disease management was viewed as improved based on the patient’s verbalization of 
understanding and a repeat MMAS-8 was conducted to objectify the improvement.  





measures were completed at different levels of the process to monitor how effective the 
intervention was. The two main levels of the process flow that project measures were assessed 
were in the level of the follow-up calls which assessed for adverse events and with the disease 
management improvement at the end of the process flow or the end TBC implementation. Refer 
to Appendix N for Project Implementation Timeline which details implementation evolution 
over time in relation to PDSA cycles.   
Evaluation of Results 
Data Maintenance and Security 
 
Data was collected for this DNP project via patient interviews, telephone interviews, 
surveys, questionnaires, and from electronic health records. Refer to Appendix I for the TBC 
Script. The data collected with patient identifiers included during patient interactions was first 
completed on paper that was stored at the clinic. The data with patient identifiers included was 
then entered into the clinic computer and saved during the duration of the project.  
When data collection via patient interviews, unique numbers were assigned to each 
participant to deidentify and protect patient information. Age was not removed, but those that 
were in the 89 and above age group were listed as “89+”.  University of Arkansas Statistical and 
Measurement Support Services (SMSS) staff and myself then accessed the deidentified data 
using only the unique patient number for analysis. Refer to Appendix H for both Patient Specific 
and Total Patient Data Collection Sheets used.  
After, all data was recorded in Microsoft Excel the remaining patient identifiers were 
destroyed. After data analysis, the project was then disseminated with the HFSC staff and 
University of Arkansas DNP committee members. Any paper documentation at the clinic was 





Act (HIPAA) policies. 
The patient data that was collected from the study was not transmitted, transported, or 
transferred to any other persons or outside of the clinic while patient identifiers were present. 
The unique identifier list that connected the patient to their number was stored in the clinic under 
my password-protected login on the clinic computer system, and only myself had access to this 
information while at the clinic. 
Evaluation of TBC Goals and Objectives 
The aim for this DNP quality improvement project was to improve medication adherence 
in heart failure patients through the implementation the TBC intervention.  The goal was to 
improve the number of medication adherent heart failure patients at a HFSC by 20% from 
baseline by March 2021.  
The first objective developed to achieve the aim was to identify all heart failure patients 
at risk for nonadherent medication behaviors at a HFSC. Throughout the implementation of 
TBC, I conducted MMAS-8 surveys with all HF patients who presented for their regularly 
scheduled HF visit in a four-week period, to identify the patients that were nonadherent. There 
were 37 total patients screened with the MMAS-8. Of the 37 patients screened, 23 were adherent 
and 14 were nonadherent. Of the 14 nonadherent patients, 12 agreed to participate in the TBC 
intervention.  
The next objective involved recognizing the potential barriers of medication 
nonadherence within the patients who had nonadherent MMAS-8 surveys. I assessed medication 
nonadherence barriers with the Medication Nonadherence Questionnaire (MNQ), which 
determined barriers that existed with the patient’s current medication taking behaviors and 





I decided that medication adherence would need to be measured at baseline and following 
the implementation of TBC through the conduction of Morisky Medication Adherence Scales 
(MMAS-8). By measuring the MMAS-8 scores at each interval, I was able to trend the changes 
throughout the intervention.  
A surveillance plan was created via telephone-based medication adherence conferences to 
aide in improving nonadherent medication behaviors following routine heart failure clinic visits. 
I conducted educational sessions at the patient’s initial clinic visits and then used the TBC script 
to guide the advisement and assessments that occurred at the follow-up telephone calls with 
patients.  
Lastly, the project aimed to improve patient outcomes through the reduction of hospital 
admissions by improving the medication adherence of prescribed heart failure regimens.  The 
literature clearly reflects that medication nonadherence contributes to diminished patient 
outcomes (Turrise, 2016; Yancy et al., 2018). By improving medication adherence, the project in 
turn improves patient outcomes through the reduction of hospital admissions and disease 
complications.  
Throughout the implementation of this project, I used the project objectives to formulate 
a process flow chart to guide the project components during implementation. See Appendix B for 
the Upgraded Process Flow Chart reflecting TBC implementation. In addition to the objectives 
and process flow, I developed project measures to guide the project in generating a successful 
product.  
Outcome Measures 
The outcome measures defined by myself were used to quantify how well TBC met the 





outcome measure included the medication nonadherence variables identified during patient 
interviews such as medication related symptoms, affordability, and forgetfulness. In addition, 
demographic data specific to all patients within the study was an evaluated outcome measure. 
Lastly, one of the most important outcome measures the project identified was the number of 
heart failure patients who had an MMAS-8 survey prior to the TBC intervention that was 
indicative of nonadherence to medication. The project then went on to detect the percentage of 
improvement in medication adherence after TBC was implemented, which was a crucial 
outcome measurement tool for determining a change in medication adherence.   
Process Measures 
The process measures were used to investigate each step of the proposed intervention to 
ensure it was implemented as it was intended, which assisted myself in maintaining competency 
and productivity.  The project used the Plan-Do-Study-Act technique to plan the project, 
implement the intervention, analyze the interventions effectiveness, and make revisions to the 
project when barriers occurred (Melnyk & Fineout-Overholt, 2019; Moran et al., 2017).   See 
Appendix N Project Implementation Timeline for weekly barriers that were identified during 
project implementation and how they were addressed as well as Appendix O for PDSA cycles.  
The process measures for this DNP project include measuring the number of heart failure 
patients at the HFSC who have participated in the TBC intervention at 1 week, 2 weeks, and 6 
weeks. This project aimed to have 75 percent participation of patients in TBC by week 6 of 
implementation. Refer to Appendix Q for Process Measures Run Charts displaying participation 
in TBC. I monitored adherence of survey administration via weekly chart reviews, monitored 
this process measure in order to ensure that staff implemented the intervention as intended.  This 





patients. Refer to Appendix Q for Process Measures Run Chart depicting researcher adherence 
with MMAS-8 administration. 
Balancing Measures 
The balancing measures of the implementation of TBC were used to determine 
unintended positive and negative effects of project implementation.  The balancing measures 
included the number of hospital admission during TBC implementation, potential for an increase 
in medication nonadherence, and the potential influx in patient correspondence with the clinic as 
compared to pre-implementation.  Refer to Appendix R for Balancing Measures Run Chart 
reflecting hospitalizations despite TBC. The identified balancing measures were important for 
this study because they were potential negative events that were expected to occur, which had the 
potential to skew the results of the study and was planned accordingly.   
Data Evaluation 
The data collected during this project was recorded daily in Microsoft Excel for storage. 
At the completion of the project the data was analyzed using the Excel Tool pack with the help 
of SMSS staff.  
Demographics 
The mean age of the participants was 55, with the youngest age of 29 and the oldest age 
of 71. There were 58% African American participants and 42% Caucasian participants. The TBC 
participants were equally represented with sex as 50% were males and 50% were females.  
The mean distance the patient was located from the clinic was 38.2 miles with a max of 
122 miles and a minimum of 5 miles. There were 33.3% retired participants, 25% unemployed 
and disabled, and 16.7% employed at the start of TBC. Of the TBC participants, 25% had 





college, and only 8.3% had finished a bachelor’s degree.  
The mean number of years since diagnosis was 3 years prior to participation in TBC. The 
patients are given a New York Heart Association functional class (NYHA FC) assessment 
between 1 and 4, with 1 being the most functional and 4 being the least with respect to their HF 
symptoms. The participants of the project had a NYHA FC range between 1 and 3, with 16.7% 
in functional class one, 58.3% and 25% in functional class two and three respectively. Refer to 
Table 1 for TBC Demographic Data.  
Select categories of demographic data were analyzed in comparison to MMAS-8 results 
to detect trends that may be linked to demographics. Education, race, and employment were 
compared using SPSS software to the MMAS-8 results, though there were no significant 




Demographic Data for TBC Participants 
 





















































Mean Number of Years Since HF 
Diagnosis (years) 3 











Note. This table reflects only demographic data for the 12 TBC participants who participated in 
the study.  
Medication Nonadherence Questionnaire (MNQ) Responses  
 When completing the Medication Nonadherence Questionnaire, the patients were allowed 
to pick three out of seventeen choices. The most common barrier for medication adherence was 
simply forgetting to take the medication (83.3%) and the second most common was in relation to 
a medication regimen that was too complex (41.7%). The third choice was tied at 16.7% for not 
wanting to take the medication, accidentally taking the wrong medication, the hospital told them 
not to take it, too many symptoms with the medication, or the medication did not seem to help 
their symptoms. In fourth, with only 8.3% choosing the options included not knowing with the 
medication was for, not being able to afford the medication, needing medications for other 
conditions more than their HF medication, and taking too many medications. Refer to Figure 1 






Medication Nonadherence Questionnaire Results 
  
Note. Patients were able to pick up to three answers on the MNQ, only questions that were 
chosen are reflected here.  
TBC Analysis 
 The mean call length for the first week follow-ups was 7.82 minutes, week two took 





































 There were two patients that despite MMAS-8 reflecting nonadherence, they declined 
participation in TBC. In addition, there was one patient that had to drop out after the week 1 
follow-up due to insurance changes. For week one follow-up there was 91.7% participation, 
week two had 58.3% participation, and by week six there was 83.3% participation. During the 
TBC follow-up calls 16.7% of patients required medication changes based on assessments from 
TBC calls, at week two zero patients required changes, and by week six 8.3% required 
medication changes during follow-up calls. Refer to Appendix Q for Process Measures Run 
Charts depicting TBC Participation at week 1, 2, and 6.  
MMAS-8 Results 
 Throughout the study there were 35 MMAS-8 surveys administered. The MMAS-8 
surveys identified 14 nonadherent patients, of which 12 (85.7%) were willing to participate in the 
TBC intervention. Refer to Figure 2 for MMAS-8 Adherence Totals. The mean pre-TBC 
MMAS-8 score for nonadherent patients was 5.17. Refer to Appendix P for RMANOVA 
descriptive statistics chart. By week one the mean score increased to 7.18, week two increased to 
a mean of 8, and by week 6 the MMAS-8 score increase continued with a mean score of 7.9. 
Refer to Figure 3 for Mean Medication Adherence Scores Pre and Post TBC Intervention. From 
pre-intervention to week 1 completion there was a 28.1% increase in MMAS-8 scores, by week 2 
there was a 54.8% improvement in MMAS-8 score from pre-implementation, week 6 was 
slightly less with 52.9% improvement, and overall there was an average of 45.3% improvement 
in MMAS-8 scores with the implementation of TBC. Refer to Figure 4 for Average Score 
Improvement Throughout TBC.  
Figure 2 






Note. There were a total of 35 MMAS-8 surveys administered over a 4-week period.  
Figure 3 
Mean Medication Adherence Scores Pre and Post TBC Intervention 
 




 MMAS-8 Adherence Totals 
Adherent: Not a Candidate for 
TBC 
Nonadherent: Willing to 
Participate in TBC 
Nonadherent: Unwilling to 
Participate in TBC 
Week 1 MMAS-8 Week 2 MMAS-8 Week 6 MMAS-8 
Pre Intervention Score 5.167 5.167 5.167 



















Mean Medication Adherence Scores Pre 





included all MMAS-8 scores available, some values were missing for those who did not 
participate every consecutive call. Blue bar is pre-MMAS-8 mean compared to Red bar for 
associated week of TBC.  
Figure 4 
Average Score Improvement Throughout TBC 
 
Note. Table reflects score improvement in comparison to pre-MMAS-8 scores.  
 A repeated measures analysis of variance (RMANOVA) was used to evaluate 
relationships in data TBC data. Refer to Appendix P for RMANOVA Output Data.  A repeated 
measures RMANOVA analysis is useful for reflecting a quantitative depiction of change to 
scores at multiple points in time in relation to a baseline result (Macey et al., 2016). The use of 
RMANOVA allows the researcher to uncover any correlation between the repeated interventions 
within the same subject group over time. In this project, the TBC intervention starts with pre-
implementation MMAS-8 scores and repeats MMAS-8 survey scores at each repeated 




















suitable choice for conclusive analysis in the data relationships.  
 The RMANOVA was conduced using a statistically significant sphericity p-value of 
0.05. The result of the RMANOVA in terms of the Mauchly’s Test of Sphericity reflected a 
score of p=0.253. Since the actual p-value of 0.253 is greater than 0.05, the project met the 
assumptions for sphericity meaning that the TBC intervention has a statistically significant 
improvement on MMAS-8 scores over time. Refer to Appendix P RMANOVA Output Data.  
 In addition, since we met Mauchly’s test for sphericity, the RMAVONA test of effect 
size was also computed. With having met the assumptions of sphericity there was a statistically 
significant effect of time of TBC on MMAS-8 scores, F(3, 18)=39.938, p=.000. Since the p value 
is less than 0.05, the values reflect a significant effect on the outcomes of MMAS-8 scores 
despite a small sample size. This tells us that if the means are perfectly equal in the general 
population, there is a 0% chance of finding the differences between means that we observed in 
this TBC study. Therefore, we reject the null hypothesis of equal means because there is 0% 
chance that the change in TBC scores happened by chance, and instead accept the alternative 
hypothesis indicating that change occurred as a result of the TBC intervention.   
TBC Results Compared to Literature 
The implementation of TBC has reflected an increase in mean adherence scores from all 
patients from an average score of 5.17 to 7.9 in those who have participated in the project by 
week 6. Patients have reached an adherent score across the board by the second week of TBC 
implementation where the mean MMAS-8 score for those who participated was 8.0. According 
to Oscalices et al. (2019), initial education sessions and structured follow-up calls have the 
potential to improve adherence by more than 17%. Studies described by Santra (2015) 





improvement in medication adherence. The implementation of TBC has found even similar 
improvements and can concur with the results in the literature, as there was an overall average 
increase in scores by 45.3% throughout TBC.  
The TBC intervention resulted in a statistically significant improvement in MMAS-8 
scores. The mean MMAS-8 scores improved from 5.167 pre-intervention, 7.182 by week one, 
8.0 by week two, and had a mean of 7.9 by week 6 following the TBC intervention. There was 
an overall improvement in the average MMAS-8 scores by 45.3% by the conclusion of TBC 
implementation.  
Discussion 
Healthcare Quality Impact  
 The goal of this DNP project was to improve patient outcomes through the cessation of 
patient medication nonadherence.  This DNP project was in alignment with the quality 
improvement goals of Healthy People 2020, which aimed to, “improve cardiovascular health 
and quality of life (QoL) through prevention, detection, and treatment” (Office of Disease 
Prevention and Health Promotion, 2020).  Interventions to reduce risk factors, increase access 
to care, increase appropriate and timely treatment, improve treatment outcomes, and reduce 
mortality were deemed necessary (Office of Disease Prevention and Health Promotion, 2020).  
TBC and methods of the like were reported as having the potential to increase access to care, 
improve adherence to treatments, improve patient outcomes, and reduce mortality, which aid in 
achieving the goals of the Healthy People 2020 campaign (Inglis et al., 2011; Knecht & 
Neafsey, 2018; Office of Disease Prevention and Health Promotion, 2020; Turrise, 2016).    
Economic and Cost Benefits   





expenditures, and a projected increase to 60 billion dollars by the year 2035; there is a need for 
improvements in heart failure management (AHA, 2017a; CDC, 2019).  The implementation of 
the TBC intervention helped with reduction of the heart failure cost of care through the reduction 
in medication nonadherence as reflected by an overall improvement of MMAS-8 score by an 
average of 45.3% throughout TBC implementation. In addition, the reduction in nonadherence 
impacts a reduction in hospital readmissions, morbidity, and mortality (Inglis et al., 2011; 
Knecht & Neafsey, 2018; Turrise, 2016).  TBC is a cost-effective way to impact the healthcare 
economic burden.  Furthermore, with the rise in use of telehealth modalities in healthcare 
delivery, insurance reimbursement is becoming a more regular occurrence for care provided by 
this method (Lori et al., 2020).  An increase in reimbursement for telehealth modalities makes 
the TBC intervention a cost-effective option for improving patient medication adherence as well 
as increasing patient access to care.  
Limitations 
 There were several limitations noted in the study implementation, the first of which was 
lack of participation in TBC with a multitude of contributing factors. One extenuating factor of 
low participation included delayed start for the implementation of the TBC intervention. Due to 
the late start the initial recruitment phase was reduced from six weeks to four weeks. A further 
extenuating factor that contributed to a small sample size and small treatment group was that the 
COVID-19 pandemic limited the number of patients that showed up for their scheduled clinic 
visit. Due to the small sample size, this may cause result variation if transferred to another 
population. 
In addition, the participants were unreachable by phone even after multiple attempts. The 





TBC intervention was approved through both the clinic and university institutional review boards 
to be completed at the clinic, as data with patient identifiers in place were not permitted to leave 
the clinic. This factor became problematic when the clinic was closed for one week due to 
inclement weather.  
 Lastly, I identified a flaw with identifying nonadherent patients with the use of the 
MMAS-8 survey. The MMAS-8 survey relies on patient report to deem adherence. There were a 
multitude of instances where the patient was identified as adherent on the MMAS-8 survey, but 
the patient had factors that signaled nonadherence during their clinic visit. Some examples of 
factors identified were lack of prescriptions filled by the patient as reported by the patients 
pharmacy, discrepancies in the frequency in which the prescription was filled, or the patient 
having no recollection of being on a medication despite having been ordered at previous visits 
with the HF specialist.  
Project Bias 
Patient Bias. The first potential bias recognized by me was the potential for the patient to 
not report their nonadherence. For example, the patient may not report adherence with the 
MMAS-8 survey despite having been nonadherent for fear of judgment. Lack of self-report of 
nonadherence also could have contributed to small sample size. 
Principal Investigator Bias. In addition to patient biases, I could have bias regarding 
information they have heard via patient discussions with clinic staff and myself prior to 
administering MMAS-8. If I knew information about the patient regarding their medication 
taking behaviors prior to talking with the patient, I may have different social cues that affect the 
responses from the patient.  





MMAS-8 scores from the initial clinic visit to the final follow-up call on week 6. The positive 
results of the study could be flawed by lack of truth from the patients at follow-up calls. When 
the patient is not in the clinic, it is easy for them to lie when answering to get off of the phone 
sooner.  
Sustainability  
 This DNP project worked very closely with the HFSC staff for proper implementation 
and modifications to meet the needs of the clinic.  With the inclusion of the HFSC staff in 
development, this project has the ability to remain in place after the conclusion of the project.  
The staff was further educated on how implementation of intervention was conducted at the 
completion of the project as to be able to independently implement it in the future to reach 
more patients and improve medication adherence.   
Recommendations 
Policy Implications 
 The implementation of TBC introduced a plan for continued use to reduce medication 
nonadherence in heart failure patients.  Evaluation of the data showed statistically significant 
changes in MMAS-8 scores with the implementation of TBC, which concludes an 
improvement in medication adherence and deems TBC an effective intervention to reduce HF 
nonadherence with medications.  Based on the project results, the use of TBC could be 
presented to other cardiology clinics in the community, state, or national level in order to 
improve adherence with HF patients throughout the United States.   
 The implementation of TBC was successful and was proven useful in improving 
medication adherence scores with HF patients at the HFSC. The clinic has the option of 





or adherence survey to include more questions for the PI to assess non-reported nonadherence 
factors in future studies. With the ability to bill for telehealth services, the clinic can use TBC 
as a way to increase revenue. In addition, the improvement in HF patient outcomes as reflected 
in with the implementation of TBC can aid in reduced hospital readmissions related to 
medication nonadherence thus increasing HF reimbursements, as the Centers for Medicare and 
Medicaid Services (2020a) provides higher reimbursement and recognition for excellence in 
the field of high HF patient outcomes.   
Translation 
Due to the nature of this DNP project with limited constraining factors, this project 
could potentially be implemented in other HF clinics.  Reliability and validity of the MMAS-8 
have been evaluated in order to ensure its ability to be used and duplicated in similar 
populations of HF patients at other HFSC locations.  This DNP project has been adapted by a 
thorough review of literature from other project studies as well as through the HFSC needs.  
Cronbach alpha levels are useful in quantifying the level of test and re-test reliability (Heo, 
Kim, & Faith, 2015).  The MMAS-8 is known to have a Cronbach alpha score of 0.83, which 
means it has a strong reliability to produce positive outcomes if initiated again with a different 
sample of participants (Heo, Kim, & Faith, 2015).  Based on the statistically significant results 
found with the implementation of TBC, development from previous studies, in conjunction 
with the reliability and validity of the MMAS-8, this project would likely do well in other HF 
clinics. With a relatively small sample size, the outcomes may differ if translated to other 
population.  
Dissemination 





evidence based change within the healthcare continuum (Fencl & Matthews, 2017). 
Throughout the implementation of the TBC intervention, I reported project data results to the 
HF specialist at least monthly through informal meetings.  At the completion of the project, I 
completed data analysis with the help of the SMSS staff at the University of Arkansas 
Fayetteville, and then the information was disseminated to the HFSC team in a summative 
presentation. In addition, the HF specialist reported a brief overview of the project findings 
with the partners within the practice.  I also conducted a presentation of data from the project 
with the doctoral committee at the Eleanor Mann School of Nursing at University of Arkansas 
(EMSON).  
Professional Reporting 
Following the completion of the DNP project and dissemination of results to the key 
stakeholders, HFSC team, and DNP committee, the DNP professional paper was revised for 
professional reporting within the medical community.  This project will be submitted to the 
Journal of Cardiovascular Nursing and the Journal of the American Association of Nurse 
Practitioners.  Due to the COVID-19 pandemic, this DNP QI project will not be presented at the 
University of Arkansas Research week in Spring of 2021 due to restrictions of gatherings. I will 
consider attending the American College of Cardiology (ACC) for their virtual scientific session 
for a presentation of my project results in May 2021 if deadlines permit (ACC, 2020).  
Conclusion 
Due to high prevalence of heart failure and ever-increasing cost burden of heart failure 
care within the United States, there has been widespread discussion regarding strategies to 
improve patient outcomes within this patient population.  Many patients with HF report some 





nonadherence leads to poor patient outcomes and increased readmission rates (Inglis et al., 2011; 
Knecht & Neafsey, 2018; Turrise, 2016).  Nonadherent patient behaviors require attention from 
healthcare providers.  This DNP project sought to provide further evidence supporting the use of 
TBC like interventions to improve medication adherence in heart failure patients. The 
implementation of TBC showed statistically significant (p=.000) modifications in patient 
nonadherent behaviors as reflected with improved MMAS-8 scores.  The project aim was met 
and results far exceeded the goals of the project. The continued implementation of TBC would 
be useful to reduce medication nonadherence, thus reducing hospital admissions, improving 
patient outcomes, and reducing mortality in HF patients being seen at a HFSC in Little Rock. In 
future studies the researcher should consider adding to the adherence measurement tool to 
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Appendix A: Global Aims  
 
 
Theme for Improvement: In order to improve patient outcomes in the heart failure population at a 
HFSC in Little Rock, AR, patients need to have proper self-management skills for medication 
adherence that are provided to them. 
Global Aim Statement 
Create an aim statement that will help keep your focus clear and your work productive: 
 
We aim to improve:  medication adherence of heart failure patients  
(Name the process) 
In: A HFSC in Little Rock 
(Clinical location in which process is embedded) 
 
The process begins with: collecting data on the reasons for nonadherence among heart failure patient 
(Name where the process begins) 
 
The process ends with: a thorough foundation of interventions to improve the patients self-efficacy and 
improved adherence with heart failure medication care plans  
(Name the ending point of the process) 
 
By working on the process, we expect: to see improved self-efficacy behaviors including medication taking 
skills and adherence to prescribed medication dosages for heart failure patients. 
                                                                                                                        (List benefits) 
 
It is important to work on this now because: if our patients continue to exhibit nonadherent behaviors with 
medication and lack of participation in their own healthcare needs, they will continue to have poor 
outcomes, poor quality of life, and increased mortality. 
                                                                                                                   (List imperatives) 
 
Create Flowchart 
Specific Aim Statement 
We will:  X increase  p improve  p decrease 
 




  (percentage) 
 
From: baseline state 
 
To/By: 20% 
(describe the change in quality or state the number/amount/percentage) 
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Note.  From “Theory at a Glance: Application to Health Promotion and 
Health Behavior (Second Edition),” by National Cancer Institute, 2005, 
(https://cancercontrol.cancer.gov/brp/research/theories_project/theory.pdf).  





















Note.  Adapted from Bohm et al., 2016; Cui et al., 2019; Knecht & Neafsey, 2016; 
Kripalani et al., 2015; Lam & Fresco, 2015; Meraz, 2020; National Cancer Institute, 2005; 
Paterick et al., 2017; Rehman et al., 2019; Santra, 2015; Silavanich et al., 2019; 
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Appendix H: Patient Specific Data Collection Sheets 
 
This data will be recorded in Microsoft Excel and computed in Qualtrics during data analysis and used for 
all of the measurement data. This is the data sheet that will be used during de-identification process when 
information is accessed through encrypted email.  
 





















































































   
 
NONADHERENCE FACTORS 
  Factor Yes No 
Adverse effects started with the medicine 
  Medication did not help/eliminate symptoms 
  Started feeling better 
  Could not afford 
  No ride to pharmacy 
  I needed medications for other Dx. More 
  Did not know it was needed 
  Simply forgot 
  Lack of belief 
  Just did not want to take it 
  Too many medications 
  Medication regimen too complex 
  Accidentally took the wrong dose/old dose 
  Did not know what it was for 
  Did not have anyone to help with medications 
  Could not reach the HF clinic staff to ask questions 
  Hospital admission changes 
  
   Which medications nonadherent with 








 Age (specific age  
listed, those 89 and 









 Age at Diagnosis 
 EF at Diagnosis 
 Most Current EF 
 Date Next EF Due 
 Functional Class 
 Stage 
  




      ARNI/ARB/ACEi/Other 
      Aldosterone Receptor Antagonist 
      SGLT-2 Inhibitor 
      Diuretic 
      Metolazone 
      Corlanor 
      Nitrates 

















Appendix H: Total Patients Data Collection Sheet 
 
DEMOGRAPHICS 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 
AGE 
           
  
SEX 
           
  
RACE 




           
  
EMPLOYMENT 




           
  
RECENT EF 
           
  
DIAGNOSES EF 
           
  
NYHC FC                         
 
 







1001           
 
  
1002   
  
    
 
  
1003   
  
    
 
  
1004   
  
    
 
  
1005   
  
    
 
  
1006   
  
    
 
  
1007   
  
    
 
  
1008   
  
    
 
  
1009   
  
    
 
  
1010   
  
    
 
  
1011   
  
    
 
  
1012               
 
 
MNQ 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 
MNQ-A 
           
  
MNQ-B 
           
  
MNQ-C 
           
  
MNQ-D 
           
  
MNQ-E 
           
  
MNQ-F 
           
  
MNQ-G 
           
  
MNQ-H 
           
  
MNQ-I 
           
  
MNQ-J 
           
  
MNQ-K 
           
  
MNQ-L 
           
  
MNQ-M 
           
  
MNQ-N 
           
  
MNQ-O 
           
  
MNQ-P 
           
  






Appendix I: Educational Materials List 
 
This will include educational materials to give the patient and an explanation of information 
regarding their medication regimen and disease process. Elsevier Clinical Pharmacology was 
used to provide educational materials, as it is the database utilized by CHI St. Vincent regarding 
medications and management of disease processes. The patient will be provided a folder at their 
initial visit with the following recourses according to their current care plan.  
 
Education for all participants: 
§ HF Action Plan 
§ Common HF Meds 
§ HF Exacerbation  
§ HF Home Instructions 
§ HF Medication Handouts (individualized) as seen below 











§ Hyperpolaziation-activated cyclic nucleotide-gated channel blockers 
• Corlanor 













In addition to the topics above, the patients will receive the “HF Quick Reference Guide” with 






















If you have these symptoms you 













If you have these symptoms 
contact the clinic within the next 
day. 
  
Call the clinic for medication 
refills BEFORE you run out.  
 












These signs mean you are 
doing well and continue your 





Name What is it for? Dosage Frequency AM Noon PM Other 
reminders 
Beta-Blocker   
 
      
ACE-
inhibitor 
        
ARB   
 
      
ARNI   
 
      
Aldosterone- 
Antagonist 
        
Diuretic 
(Primary) 
        
Diuretic 
Booster 
        
Digoxin   
 
      
Nitrate   
 
      
SGLT-2 
Inhibitor 
        
Other   
 
      
 New Symptoms: 
Questions for the Doctor: 
Next Tests/Return to Clinic: 
Appendix I: HF Quick Reference Guide 
Note. Adapted from Heart Failure Action Plan. Clinical Pharmacology [Internet]. Tampa (FL): Elsevier. c2017- [cited 2020 June 16]. 






Appendix I: TBC Script 
 
Introduction: Hello I am Diana Broadway calling from Dr.Waqas’ office at HCA of LR.  We met at your last office 
visit when we talked about your participation in a study to improve your medication taking skills and better your 
heart failure management. This call will take about 15-20 minutes, there are 20 total questions followed by a brief 
time at the end for questions. It will be helpful if you refer to your HF Quick Reference Guide as we go through the 
call. Is now a good time? Do you have any questions before we begin? 
 
1. What medications have you been taking for your HF? Dosages? Frequency? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
2. Have you forgotten any doses of your HF medications? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
3. How comfortable are you that you can take your medications as they are ordered? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
4. What might be some reasons that you may not take your medications? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
5. Can you tell me what your HF medications are for (why are they important and what do they do)? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
6. How do you remember to take your medications? Do you have any specific cues you use? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
7. What do you think would help you with taking your medications? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 




9. Have any other medical providers seen you and made any changes to your HF medications? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
10. Do you have any questions about any of your HF medications? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
11. Have you been admitted to the hospital since your last HF clinic visit? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 















Appendix J: Medication Nonadherence Questionnaire 
 
The following are common reasons why patients do not take their medication.  Check the TOP 3 factors 
that apply to you. 
 




A____Too many new symptoms started with taking the medication. If checked, what symptoms did you 
experience ___________________________ 
 
B____The medicine did not seem to help my symptoms. 
 
C____I started feeling better so I stopped taking the medication. 
  
D____I could not afford the medication.  If checked, why (ex: No/Lack of income, no insurance, 
copayment too high.) __________________________ 
 
E____I did not have a ride to take me to the pharmacy to get my medications. 
 
F____I needed medications from my other conditions more.  
 
G____I did not know I needed to take that medication. 
 
H____I simply forgot to take that medicine. 
 
I____I did not believe that it would help my condition. 
 
J____I just did not want to take it.  
 
K____I take too many medications. 
 
L____The medication regimen was too complex. (ex: Too many pills at one time, too many times per day 
that I had to take it, the time of day I had to take it was hard to abide by). Please specify what 
makes the regiment too complex _______________________________ 
 
M____I accidentally took the wrong dose or an old dose of the medicine. 
 
N____I did not know what the medication was for. 
 
O____I did not have anyone at home to help me with my medications.  
 
P____I could not reach any staff members at the clinic to ask questions.  
 






























Note.  From “Predictive validity of a medication adherence measure in an outpatient 






Appendix K: Needs Assessment Script/Questionnaire 
 
Heart Failure Needs Assessment Summary from Key Influencers 
 
I really appreciate you taking a few minutes to talk with me about your thoughts on the care being 
provided to heart failure populations.  The questions I am about to ask you are intended to identify a need 
for improving care of heart failure patients.  All answers will be confidential.     
 




• RN (2) 
• PA (1) 
• APRN (2) 
• MD (1) 
 
Average time in current role: 2.5 years 
 
What gaps in care have you noted with the heart failure population? Participants spoke freely about 
ideas and listed are common themes with number of times mentioned: 
 
• Nonadherence with medications and diet (4) 
• Lack of access to healthcare (1) 
• Patient’s are not on guideline therapy when consulted to heart failure team (1) 
• Referred to heart failure team late in prognosis (1) 
 
What specific demographic of patients within your heart failure patients do you feel has a need for 
change? (For example, newly diagnosed patients, older patients, Hispanic patients, female patients, 
etc.) Participants spoke freely about ideas and listed are common themes with number of times 
mentioned: 
 
• Older males (3) 
• Older females (2) 
• Obese patients (1) 
• Newly diagnosed patients (2) 
• Young patients (2) 
 
What project do you think could benefit the care of the heart failure patients? Participants spoke 
freely about ideas and listed are common themes with number of times mentioned: 
 
• Education of patients on long term disease expectations (3) 
• What members of the care team do for their care (2) 
• Education on dietary needs in the heart failure clinic (2) 
• Education on Medication regimen and why they are important for adherence (2) 
• Education on the importance of adherence with Follow-ups (2) 
 





about ideas and listed are common themes with number of times mentioned: 
 
• Patient adherence and willingness (3) 
• Lack of time (2) 
• Patient poverty (1) 
• Literacy level (2) 
 
What do you think are the key factors for the patient to stay out of the hospital? Participants spoke 
freely about ideas and listed are common themes with number of times mentioned: 
 
• Patient adherence with medication, diet, and follow-ups (5) 
• Fluid management (1) 
• Coordinated care between providers (1) 
• Preventative care at early heart failure stages (1) 
• Support of family and community (1) 
 
What is the current process for information transfer between the HFSC and Primary Care 
Providers? Participants spoke freely about ideas and listed are common themes with number of times 
mentioned: 
 
• Fax of visit notes from Heart Failure specialist to the PCP on patient’s chart (6) 
 
What information is given to the patient at their follow up appointments? (I.e.  Medication list, 
ECHO report, etc.) Participants spoke freely about ideas and listed are common themes with number of 
times mentioned: 
 
• Medication changes (4) 
• Testing needs and results (1)  
• Follow-up time frame (1) 
• Education of diet and vital sign monitoring (2) 
• Plan of care (1) 
• Short term expectations (2) 
• Long term expectations (2) 
• Educate on emergency and urgent problems to monitor for (1) 
 
Do you ever have calls from primary care providers to discuss the heart failure patient’s plan of 
care? Or, if PCP do you call to discuss plan of care with heart failure team? Participants spoke freely 
about ideas and listed are common themes with number of times mentioned: 
 
• No (5) 
• Yes (0) 
• Unsure (1) 
 
Do you believe the patient’s with the highest readmission are those with newly diagnosed heart 
failure or established patients? Participants were prompted with following and recorded by number of 
times mentioned: 
 





• Established (2) 
• Mix of both (2) 
 
Do you believe the patient’s who have the most problems with hospital readmissions see their PCP 
or other providers in the time before being admitted to the hospital? Participants spoke freely about 
ideas and listed are common themes with number of times mentioned: 
 
• No (2) 
• Yes (4) 
 
What are the core measures for the heart failure patient upon discharge from the hospital and 
continued once they return home? Participants spoke freely about ideas and listed are common themes 
with number of times mentioned: 
 
• Known EF (1) 
• ACR/ARB/ARNI (4) 
• Beta blocker (4) 
• Follow up in 2-4 weeks with heart failure specialist (2) 
• Diuretics (2) 
• Unsure (1) 
 
 
Are you willing to help develop a program that seeks to improve heart failure patient quality of life 
through improving gaps within their healthcare needs? 
Participants spoke freely about ideas and listed are common themes with number of times mentioned: 
 
• Yes (6) 




























My name is Diana Broadway and I am a nurse practitioner student with the University of 
Arkansas Fayetteville.  I am partnering with this HFSC in LR to develop a new study to help 
improve medication adherence in the heart failure population at this clinic.   
 
1) Survey Purpose: 
 
To help the HFSC better understand the reasons for patient nonadherence to medication 
regimens your medication taking habits will be assessed with the Morisky Medication Adherence 
Survey, which will aide the clinic in better understanding how to help you understand and 
control your disease and the medications needed to manage it, and to help improve medication 
taking skills moving forward to keep you out of the hospital. This survey is a new addition to 
your clinic visit in order to determine your eligibility to participate in this study.  
 
2) Program Procedures: 
 
As a participant in this study, you will first be asked to complete the Morisky Medication 
Adherence, 8-question survey about your medication taking habits.  If you have any answers on 
the survey that reflect a barrier to taking medications as they are prescribed, you will be eligible 
for the study. You will then be asked to complete a short questionnaire regarding the reasons you 
could not take your medication regimen as it was prescribed.  
 
If you have not experienced any barrier to taking your medications as reflected in the MMAS-8 
survey, then you will not be chosen to further participate in the study. Should your MMAS-8 
survey reflect that you have no current problems with your medications, the survey information 
and all information collected today will not be saved and all documents will be destroyed 
according to current clinic policy.  
 
The survey and questionnaire should take only a couple of minutes.  The entire study is 
completely voluntary and you can opt out at any time.   
 
After the initial completion of the survey, I will be conducting a brief phone call in 1 week, 2 
weeks, and 6 weeks to follow up with you about your medications and provide guidance to you 
about your heart failure.   
 
3) Confidentiality and anonymity 
 
The survey will be completed with a healthcare provider as to assist you with any questions you 
may have during the survey. All patient data that is collected will be stored in a coded manner 
and handled to the extent allowed by the law and the University policy.  
 







The program and all its components have received IRB clearance from the University of 
Arkansas Fayetteville and this HFSC.  Please direct any questions you have regarding the 
permissions received to IRB at University of Arkansas Fayetteville.  If you have any questions 
regarding your rights as a research participant contact the research ethics coordinator for the 











































Appendix M: Patient Consent Form 
 
IMPLEMENTATION OF TELEPHONE-BASED MEDICATION ADHERENCE 
CONFERENCES (TBC) TO IMPROVE HEALTH OUTCOMES IN HEART FAILURE 
PATIENTS  
  
PRINCIPAL INVESTIGATOR  
Diana Broadway 
University of Arkansas Eleanor Mann School of Nursing 





Dr. Susan Patton 
University of Arkansas Eleanor Mann School of Nursing 
606 N.  Razorback Rd. 
1-479-575-3907 
skpatton@uark.edu 
PURPOSE OF PROJECT 
 
You are being asked to take part in a doctoral nurse practitioner student project.  Before you 
decide to participate in this project, it is important that you understand why the project is being 
done and what it will involve.  Please read the following information carefully.  Please ask the 
principal investigator if there is anything that is not clear or if you need more information. 
The purpose of this project is to improve medication-taking skills of heart failure patients at this 
heart failure specialty clinic. 
This project’s aim is to improve the number of medication adherent heart failure patients at this 




Signing this consent represents your willingness to participate in this TBC quality improvement 
project.  
During the TBC intervention process, you will be asked to participate in the following: 
• Complete the MMAS-8 survey to identify preliminary medication barriers in current 
medication taking practices.  
• Based on your score on the MMAS-8 survey, the brief survey used to determine how you 





to complete a questionnaire about the reasons for which you were unable to take your 
medications as ordered.  
• Undergo a brief education session at this initial clinic visit today that outlines your heart 
failure diagnosis including what heart failure means, your heart failure medications 
prescribed at this time, medication side effects and reasons for use, medication dosages 
and frequencies; and will include a plan for follow-up telephone conferences. 
• You will then be contacted by this PI at 1 week, 2 weeks, and 6 weeks following this 
initial visit to follow-up with you about your heart failure medication regimen. At each 
visit this PI will complete another brief education with an open dialog allowing for you to 
ask questions and you will be asked to repeat the MMAS-8 survey with each phone call.  
RISKS 
There are minimal health risks involved in this study. All therapies will be prescribed by your 
heart failure specialist and in concordance with your predetermined regimen. The only risk 
involved may include the adverse effects from dosage changes made to your care plan by your 
heart failure specialist if you are not or have not been truthful about your medication regimen.  
 
BENEFITS 
Benefits to participating in this project include a potential improvement in your health outcomes 
such as reduced hospital admissions, reduced disease progression, and reduced morbidity and 
mortality as a result of amended medication nonadherence. 
CONFIDENTIALITY 
The responses to the surveys will be recorded as part the medical records for this project. The 
identifiable information will be kept on the information until the completion of this study. At the 
end of the study all identifiable information will be destroyed and only deidentified information 
will be used.  
The principal investigator will keep all data collected at the clinic until assigning each patient a 
unique number deidentifies it and the deidentified data will then only be accessed via encrypted 
email. Notes, interview discussions, and any other identifying participant information will be 
secured in locked file storage in the personal possession of the principal investigator or heart 
failure clinic staff at the clinic. At the completion of the study, all computer information will be 
destroyed, passwords will discarded, and all paper information will be shredded and disposed of 
in accordance with clinic policies.  
 
CONTACT INFORMATION  
 
If you have questions at any time about this project, or you experience adverse effects as the 
result of participating in this project, you may contact the principal investigator, whose contact 





participant, or if problems arise which you do not feel you can discuss with the Principal 




Your participation in this project is voluntary.  It is your decision whether or not to take part in 
this project.  If you decide to take part in this project, you will be asked to sign this consent form.  
After you sign the consent form, you are still free to withdraw at any time and without giving a 
reason.  Withdrawing from this project will not affect the relationship you have with the clinic, 
your heart failure specialist, or with the principal investigator.  If you withdraw from the project 
before data collection is completed, your data will be returned to you or destroyed as stated 




I have read and I understand the provided information and have had the opportunity to ask 
questions.  I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason and without cost.  I understand that I will be given a copy of this 
consent form.  I voluntarily agree to take part in this project.   
 
 
































































Appendix O: PDSA Cycles 
PDSA Implementation Week 1 
OBJECTIVE: Obtain 90% participation in TBC of those who score <8 on MMAS-8 survey 
Change Idea: Determine those who score as non-adherent on MMAS-8 and discuss the importance of improving 
medication-taking behaviors in order to gain the most participation in TBC throughout the 6-week period. 
  Person 
Responsible  
Due Date 
Plan: Determine the best way to approach patients in order to gain their 
participation. Identify ways to be more efficient with data collection.  
PI 1/26/21 
Do: On 1/19/2021, I received the final IRB approval from the University 
IRB. I began implementation of the MMAS-8 survey and in person 
medication education for those scoring <8 on MMAS-8 that same day. With 
implementation I have had fewer participants identified as nonadherent than 
expected. I did have one patient decline to be in the study, which led me to 
think I need to be sure I am keeping my wording in a manner that encourages 
participation.  
University IRB, 
Site IRB, PI 
1/26/21 
Study:  On 1/19/2021 I administered four MMAS-8 surveys resulting in two 
non-adherent scores. Of those two non-adherent scores, both patients were 
willing to participate in the study. On 1/20/2021 I administered 8 MMAS-8 
surveys with three reflecting non-adherent scores, only two out of three 
patients were willing to participate in the study. I learned that I need to be 
aware of wording to encourage participation, to make sure that lack of 
participation is not due to wording making the study appear undesirable. I 
also missed a few questions on the demographic questions the first day that I 
was sure to ask the second day and the remaining days.  
PI 2/17/21 
Act: Now that I have patients willing to participate I will plan to follow up 
with them according to schedule. I will also plan to continue determining 
ways to better gain participation from all participants that score <8 on 
MMAS-8. In addition, I will plan to start recording and analyzing the data for 
trends. I have also begun highlighting questions frequently skipped when 
interviewing participants in order to not forget them moving forward.  
PI 2/17/21 
PDSA Implementation Week 2 
OBJECTIVE: Obtain a larger sample size for TBC intervention in those who score <8 on MMAS-8 
Change Idea: Implementation of TBC intervention to improve medication adherence in the greatest amount of 
patients to render the study statistically significant for the heart failure population.  
  Person 
Responsible  
Due Date 
Plan: Determine the best way to approach patients in order to gain their 
participation. Determine the appropriate length of time for implementation to 






Do: On 1/18/2021 I discussed the potential changes that may be needed for 
the TBC timeline of implementation with my chair due to delays with IRB 
approval. On 1/19/2021, I received the final IRB approval from the 
University IRB. I began implementation of the MMAS-8 survey and in 
person medication education for those scoring <8 on MMAS-8 that same 
day. With implementation I have had fewer participants identified as 
nonadherent than expected. In addition, due to COVID-19 many patients 
have not shown up for appointments or have been seen via telehealth. Based 
on the approval of my project and the clinic set up for telehealth visits, it is 
not appropriate for implementation via telehealth for the initial TBC visit.  
University IRB, 
Site IRB, PI 
1/27/21 
Study:  On 1/19/2021 I administered four MMAS-8 surveys resulting in two 
non-adherent scores. Of those two non-adherent scores, both patients were 
willing to participate in the study. On 1/20/2021 I administered eight 
MMAS-8 surveys with three reflecting non-adherent scores, only two out of 
three patients were willing to participate in the study. Implementation on 
1/26/2021 resulted in one nonadherent patient, however this same patient 
may not be able to complete the follow-ups due to a change of care for 
insurance reasons. 1/27/2021 only one MMAS-8 score reflected 
nonadherence. I have five participants with one patient that I will include 
until he finds care with another provider. For the first week of TBC follow-
up phone calls I had 100% participation with the four patients I called. So far 
I have learned that I will have a much smaller sample size than I had 
anticipated for reasons that were unforeseen when planning.  
PI and Project 
Chair 
1/27/21 
Act: Now that I have patients willing to participate and I have recorded the 
data in Qualtrics, I will plan to analyze the data. I have made appointments 
with the ESRM and SMSS staff to aide me in appropriate data collection 
strategies, analysis strategies, and to aide in identifying the best way to report 
a small sample.  
PI, SMSS Staff, 
ESRM staff 
2/17/21 
PDSA Implementation Week 3 
OBJECTIVE: Obtain a larger sample size for TBC intervention in those who score <8 on MMAS-8 
Change Idea: Determine barriers that exist with TBC in order to improve patient cooperation with follow-up calls.  
  Person 
Responsible  
Due Date 
Plan: During the initial clinic visit for TBC the patient is asked the best 
phone number and time to be reached by the PI. The PI needs to determine 
the best way to approach patients in order to further the chances of their 
participation during follow-up calls. When patients do not participate, what is 
the best approach to continue their follow-up processes. Determine an 
alternate strategy for reaching patient who do not answer or participate when 
called for follow-up.  
PI 2/10/21 
Do: I began implementation of the MMAS-8 survey and in person 
medication education for those scoring <8 on MMAS-8 on 1/19/20. With 
implementation I have had fewer participants identified as nonadherent than 
expected. Of the few participants in TBC so far, several have not been 
responsive to follow-up phone calls for week 2 follow-ups. The PI has tried 
calling two times per day to reach the patients. If no answer on the first call, 
the PI leaves a voicemail if possible in order to let the participant know that 
the call is from the clinic and not a telemarketing call.   
PI 2/10/21 
Study:  TBC has had 100% administration of the MMAS-8 survey for weeks 
1 and 2, and 95% on week 3 which was related to a mix up with patient name 
and appointment time. There are a total of 10 patients in TBC as of 2/3/2021. 
Six patients had scheduled TBC follow-up calls this week with only 67% 






Act: The PI will plan to attempt a follow-up call one week late for those who 
did not answer for their follow-up call at the scheduled time. If the patient 
does not respond at the one-week late attempt, the PI will then wait until their 
next regularly scheduled follow-up. This will then be listed as a limitation for 
the study.  
PI 3/29/21 
PDSA Week 4 of Implementation 
OBJECTIVE: Obtain a larger sample size for TBC intervention in those who score <8 on MMAS-8 
Change Idea: Determine barriers that exist with identifying patients who are nonadherent when MMAS-8 reflect 
adherence.  
  Person 
Responsible  
Due Date 
Plan: During initial MMAS-8 surveys, the PI has identified patients who 
report being adherent on the MMAS-8, but in fact there are factors of their 
medication regimen that have been intentionally or unintentionally omitted.  
PI 2/10/21 
Do: During the initial clinic visit for TBC the patient is asked the eight 
question that are included in the MMAS-8. The PI scores the MMAS-8 
survey and patients are asked to participate if the patient is nonadherent to 
any degree. Since planning and implementation has already begun with 
current project design, limitation or recommendations section should include 
more components for assessing medication adherence. The PI needs to 
determine a plan for future studies that can include an assessment component 
that allows the PI to include a patient when extenuating factors of medication 
nonadherence exist outside of their MMAs-8 report.  
PI 2/10/21 
Study:  TBC has been using the MMAS-8 survey to identify patients who are 
nonadherent to HF medication regimens. During the implementation process, 
the PI has identified a barrier in patient inclusion for the study. There have 
been several circumstances where patients have reported or nurses have 
discovered through speaking with patient pharmacies that they have been 
missing a medication in their regimen. Though despite the omitted 
medication or medications, the patient still reports that they have been 
adherent on their MMAS-8 survey.   
PI 4/5/21 
Act: The PI will plan to include the identified inclusion barrier in the 
recommendations for future research section and in the limitations section 
when reporting the study findings.  
PI 4/5/21 
PDSA Week 5 of Implementation 
OBJECTIVE: Obtain a 75% participation in TBC intervention at each follow-up interval.  




Responsible  Due Date 
Plan: During TBC follow-ups the PI experienced reduced participation at 
week 2 follow-ups with TBC intervention. The PI had intentions to follow-up 






Do: Although the PI planned to follow-up at multiple times during the week 
scheduled for follow-up, the PI was unable to do so due to inclement weather 
within the central Arkansas region. The PI was only approved by IRB to 
access patient personal identified information within the clinic. Since the 
clinic was closed for several days during the intended follow-up period, the 
PI was unable to follow the plan to follow-up on multiple days to gain more 
participation.  
PI 2/17/21 
Study:  The PI was unable to follow-up at multiple intervals throughout the 
week of follow-up due to clinic closures. There was no change in 
participation as the PI was unable to make needed changes.  
PI 2/17/21 
Act: The PI will plan to discuss the lack of access the patient identifiers 
outside of the clinic as a limitation for the study. The PI will also plan to 
implement the planned strategies for increased participation at the follow-up 
calls conducted when the clinic is in operation. 
PI 2/24/21 
PDSA Week 6 of Implementation 
OBJECTIVE: Obtain a 75% participation in TBC intervention at each follow-up interval.  
Change Idea: Attempt to reach patient on multiple days within scheduled follow-up week.  
  
Person 
Responsible  Due Date 
Plan: During TBC follow-ups the PI experienced reduced participation at 
weekly follow-ups with TBC intervention. The PI  determined that a 
correction would be plausible with multiple days of follow-up attempts 
during the week of planned follow-up.   
PI 2/17/21 
Do: The PI started calling all patients scheduled for follow-up within the 
week on Monday, with additional calls each day until reached.  
PI 2/24/21 
Study:  Due to the increased frequency of calls, there was an influx in the 
amount of return calls received by the nurses at the clinic. When nurses 
received return calls they were unsure if the PI had attempted to reach the 
patient due to lack of documentation for failed calls.  
PI 2/24/21 
Act: The PI will plan discussed the best possible way to alleviate the 
challenge for the nurses. The solution that was concluded was that the PI 
would send a message to the nurse even when the PI had failed to reach the 






















Appendix Q: Process Measures Run Charts 
Run Chart 1 
 
Process Measure: Patient Participation in TBC by Week 
 
Note. This table reflects the percent of patient participation in TBC follow-up calls throughout 
TBC starting at week 2 of implementation, as week 1 was only patient recruitment. X-axis 
represents week of implementation and Y-axis reflects percentage of participation.  
 
Run Chart 2 
 
Process Measure: Overall TBC Patient Participation by Follow-up Week 
 
Note. This table reflects the percent of patient participation in MMAS-8 surveys during TBC at 
initial, week 1, 2, and 6. X-axis represents week of implementation and Y-axis reflects 
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Run Chart 3 
 
Process Measure: Researcher Adherence of Pre-MMAS-8 Administration  
 
 
Note. This table reflects the percent of researcher participation in administering MMAS-8 
surveys during TBC recruitment phase. X-axis represents week of recruitment and Y-axis 
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Appendix R: Balancing Measures Run Chart 
 
Run Chart 4 
 
Balancing Measure: Non-HH Hospitalizations Despite TBC 
 
Note. This table reflects the number of hospitalizations per week of implementation. None of the 
hospitalizations in this table were related to HF diagnosis, but rather they were other causes. X-
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Appendix S: TBC Budget 
 
Budget for TBC Implementation 
Paper for TBC Materials (2 reams) $10 
Folders for Initial TBC Education (12) $5 
Lock for File Cabinet at Clinic $10 
File folders for PHI Clinic Storage $20 
File Lock Box $25 
    
Total $70 
 
